Examining the Efficacy of Antibiotics and the Proteomic Response in the Treatment of Staphylococcus aureus Biofilms Grown In-Vitro. by Schroeder, Kaitlin Alayna
 
 
EXAMINING THE EFFICACY OF ANTIBIOTICS AND THE PROTEOMIC RESPONSE IN THE 
TREATMENT OF STAPHYLOCOCCUS AUREUS BIOFILMS GROWN IN-VITRO.  
By 
Kaitlin Alayna Schroeder 
Thesis 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
MASTER OF SCIENCE 
in 
Chemistry 
December, 2011 
Nashville, Tennessee 
Approved: 
Professor Richard M. Caprioli 
Professor Eric P. Skaar
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2011 by Kaitlin Alayna Schroeder 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my amazing mother, Diana, who has supported me in every decision I’ve made from 
start to finish and without whom I would have accomplished nothing. With love and 
adoration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
ACKNOWLEDGEMENTS 
 
 This work would not have been possible without the funding of the Vanderbilt 
University Chemistry Department and the constant guidance and support of my 
principal investigator Dr. Richard Caprioli, my collaborator Dr. Eric Skaar, and the 
members of the Mass Spectrometry Research Center. I am especially indebted to Dr. 
Richard Caprioli who has been incredibly supportive of my career goals and who worked 
with me to develop this work. Thank you for pushing me. 
 I am grateful to those members of the lab who allowed me to present them with 
ideas and who helped me to develop my research. Special thanks to Erik Todd, David 
Rizzo, Chad Chumbley, Patrick Rawhouser, Kerri Grove, and Jessica Moore Hooten for 
their encouragement, technical support, and for their friendship. 
 I would also like to thank Hayes McDonald for his assistance in performing the 
LC-MS/MS experiments included in this thesis. Thank you for your guidance and 
patience and for your enthusiasm. 
 I am grateful for the support of my family as well, especially my mother to whom 
this work is dedicated. I would like to thank my parents and grandparents for their 
guidance and love. 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE OF CONTENTS 
 
           Page 
 
DEDICATION  iii 
ACKNOWLEDGEMENTS  iv 
LIST OF TABLES  vii 
LIST OF FIGURES  viii 
 
Chapter 
 
I. INTRODUCTION  1 
 
 Bacterial Biofilms  1 
 Biofilm Formation  2 
 Staphylococcus aureus, Virulence Factors, and the Peptidoglycan  4 
 Ampicillin  6 
 Summary  7 
 
II. TRACKING DRUG DIFFUSION AND PROTEIN CHANGES ACROSS  
 A STAPHYLOCOCCUS AUREUS BIOFILM EXPOSED TO AMPICILLIN  
 USING MALDI IMS  9  
 
 Introduction  9    
 MALDI Imaging Mass Spectrometry  9 
 Imaging Bacterial Proteins  11 
 Methods and Materials  14 
  Materials  14 
 Determining a Proper Matrix  14
 
 
 Sample Preparation  15
 Analysis  16 
 Determining Biofilm Thickness  17 
 Results  18 
 Discussion  24 
 
III. EVALUATING PROTEIN GRADIENTS ACROSS A TREATED  
STAPHYLOCOCCUS AUREUS BIOFILM USING LIQUID CHROMATROGRAPHY  
TANDEM MASS SPECTROMETRY  27 
 
 Introduction  27 
  Liquid Chromatography Tandem Mass Spectrometry  27 
  Strong Cation Exchange (SCX) Chromatography  28 
  MudPIT  29 
 Methods and Materials  31 
  Materials  31 
 Counting Bacteria  32 
 Sample Preparation  33 
 Short Stack  35 
 In-gel Digestion and Extraction  35 
 Analysis  37 
 Results  38 
 Discussion  44 
 
IV. SYNOPSIS AND CONCLUSIONS  48 
 
APPENDIX  51 
A. Penicillin-Binding Protein 1  51 
B. Penicillin-Binding Protein 2  53
 
 
C. Penicillin-Binding Protein 3  58 
D. Penicillin-Binding Protein 4  60 
E. Cell Division Protein FtsQ  61 
F. General Stress Protein-Like Protein  63 
G. Methicillin Resistance Expression Factor FemA  83 
  
REFERENCES  97 
vii 
 
LIST OF TABLES 
 
Table           Page 
1.  Determination of the average number of colony forming  
 units (CFUs) per square millimeter of bacterial biofilm  38 
 
2. Summarized results for the defensive proteins identified which  
 display trends across the biofilm  39 
 
3. Normalized LC-MS/MS MudPIT results for sections 1-6 taken  
 from a Staphylococcus aureus biofilm treated with ampicillin  41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
LIST OF FIGURES 
 
Figure           Page 
1.  A Staphylococcus aureus biofilm on the surface of a medical  
 catheter removed from a patient  2 
 
2.  Schematic representation of the growth and development of  
 a bacterial biofilm  3 
 
3. Structure of the Gram-positive peptidoglycan and cell wall  6 
 
4. Schematic representation of the steps involved in profiling and  
 IMS analysis of tissue samples  10 
 
5. Co-registered IMS and MRI images displaying signals  
 associated with Calprotectin (m/z 10,165) as well as a 
  structural protein (m/z 5,020)  12 
 
6. An example MALDI MS/MS spectrum for m/z 350.1, ampicillin,  
 showing three drug specific fragment peaks and a MALDI MS/MS  
 spectrum for pure sinapinic acid matrix  18 
 
7. Drug imaging for the mass range [m/z 159.58-160.58 plus 173.58-174.58]  
 for a control biofilm treated with ddH2O and for a biofilm exposed  
 to ampicillin  19 
 
8. Examples of IMS revealing various proteins specific to  
 exposure to ampicillin in a Staphylococcus aureus biofilm  20 
 
9. Examples of IMS revealing various proteins specific to  
 structural components of the Staphylococcus aureus biofilm  21 
 
10. Example spectra from two Staphylococcus aureus biofilms exposed  
 to ampicillin, with emphasis on the range m/z 2600-3600 featuring  
 proteins related to biofilm structure  22 
 
11.  Determination of the average thickness and the average number 
 of bacterial layers present in a Staphylococcus aureus biofilm treated  
 with ampicillin  23 
ix 
 
 
12. Schematic representation of the basic steps involved in the  
 analysis of a complex protein mixture via MudPIT  30 
 
13. Schematic showing the general location of each 4x4 mm section  
 cut from a Staphylococcus aureus biofilm for analysis via LC-MS/MS  34 
 
14. Plot displaying the normalized spectral counts for each section  
 for penicillin-binding protein 1 and penicillin-binding protein 4  42 
 
15. Plot displaying the normalized spectral counts for each section  
 for methicillin resistance expression factor FemA and penicillin-binding  
 protein 4  42 
 
16. Plot displaying the normalized spectral counts for each section  
 for cell division protein FtsQ and penicillin-binding protein 1  43 
 
17. Plot displaying the normalized spectral counts for each section  
 for general stress protein-like protein  43 
 
 1 
 
CHAPTER I 
 
INTRODUCTION 
 
Bacterial Biofilms  
 Microbial biofilms form when microorganisms irreversibly adhere to a surface, 
producing extracellular polymers that facilitate adhesion. These microorganisms may 
attach to living or non-living material and are common in indwelling medical devices 
such as catheters (Figure 1) and artificial hearts as well as on surfaces in water 
treatment facilities and the food industry.1  
 Biofilms possess very different characteristics from freely suspended organisms 
or bacterial colonies grown on an agar surface1. They grow upwards from the surface in 
layers and are inherently antibiotic resistant. The layered structure of the bacteria 
means that depending on their location within the biofilm, the microorganisms are 
experiencing different environmental conditions which in turn produce physiological 
differences making it difficult to treat the entire film2. What may kill the bacteria in one 
region of the film may not have any effect on another region. As a result, infections 
resulting from biofilm introduction into the body are very difficult to eradicate. 
 Biofilms may be composed of Gram-positive or Gram-negative bacteria or yeasts. 
The majority of biofilms which develop on indwelling medical devices are composed of 
multiple species of bacteria. Species commonly isolated from these types of devices 
include the gram-positive Staphylococcus aureus and Staphylococcus epidermidis and 
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the Gram-negative Escherichia coli and Pseudomonas aeruginosa. Bacteria capable of 
forming biofilms usually originate from the patient’s skin microflora, exogenous 
microflora from medical personnel, or various other contaminated sources.1  
 
 
 
 
 
Figure 1. A Staphylococcus aureus biofilm on the surface of a medical catheter removed 
from a patient. Electron micrograph magnified 2363x.2 
 
 
Biofilm Formation 
 Biofilm formation begins with freely suspended bacteria which attach to a 
surface via weak, Van der Waals forces. The cells can then anchor themselves more 
permanently using cell adhesion structures such as pili2. The bacteria undergo 
maturation and form extracellular polymeric substances (polysaccharides), which 
surround and encase the cells, linking them to one another in a sheet-like structure. 
These extracellular polysaccharides may also prevent penetration of antimicrobial 
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agents into the film and impair opsonization by the host3. Following maturation, the 
biofilm will release cells into the environment enabling the bacteria to spread and 
colonize other surfaces (Figure 2)2.  
 
 
Figure 2. Schematic representation of the growth and development of a bacterial 
biofilm. Five steps in the development of a biofilm: (1) Initial Attachment, (2) Irreversible 
Attachment, (3) Maturation I, (4) Maturation II, (5) Dispersion. Each stage in the 
development of a biofilm is paired with a photomicrograph image of a developing 
Pseudomonas aeruginosa biofilm.2 
 
 
The growth and attachment rates of biofilms are dependent on several factors 
including the type of fluid the device is exposed to, the flow rate of fluid through the 
device, and the physicochemical characteristics of the surface. Temperature, the 
presence/absence of an antimicrobial drug in the system, and the nutrient composition 
of the medium also play a role in biofilm development on surfaces and in the body.1 
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Staphylococcus aureus, Virulence Factors, and the Peptidoglycan  
 Staphylococcus aureus is a facultative, anaerobic, gram-positive, coccal bacteria 
typically found on the surface of the skin and inside the human nose4. It is the most 
common species of staphylococcus to cause staph infections and is one of the five most 
common causes of nosocomial infections, infections resulting from treatment in a 
hospital or health care center. S. aureus can cause a wide range of diseases and 
infections including boils, abscesses, pneumonia, endocarditis, toxic shock syndrome, 
and sepsis5. 
 When grown on tryptic soy broth (TSB) agar plates the bacteria form large, 
round, golden colonies. They derive their color from the carotenoid pigment 
staphyloxanthin, which also acts to protect the bacteria from reactive oxygen species 
released by the immune system in response to infection6,7. Staphyloxanthin acts as a 
virulence factor, a gene product produced by a pathogen which enables it to colonize a 
host and enhances its potential to cause disease. Other virulence factors associated with 
this species of bacteria include fibronectin binding protein A (acts as a bridge between 
bacteria and the host cell), elastin-binding protein (aids in the colonization of host tissue 
and may play a role in the regulation of cell growth), and clumping factor A (binds to 
complement proteins released by the host in response to infection)8.  
 S. aureus also feature a number of surface proteins, bound to the cell by Sortase 
A, which help them to survive inside a host organism. For example, Protein A, an IgG 
binding protein, acts as an immunological disguise and inhibits phagocytic engulfment.9  
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 S. aureus also produces an enzyme called β-lactamase which breaks open the β-
lactam ring of β-lactam antibiotics such as penicillin and ampicillin, deactivating their 
antibacterial properties5,10. This compound is responsible for many bacterial strains’ 
resistance to β-lactam antibiotics. 
 Gram-positive bacteria such as S. aureus feature a layer within the cell wall 
known as the peptidoglycan. This cell wall layer is also present in gram-negative bacteria 
although it is significantly thinner. The peptidoglycan is composed of interlocking chains 
of identical peptidoglycan monomers consisting of two sugars: N-acetylglucosamine 
(NAG) and N-acetylmuramic acid (NAM). The peptidoglycan monomers are synthesized 
in the cytosol and transported to the membrane by a carrier molecule called 
bactoprenol (Figure 3).11  
 S. aureus bacteria reproduce asexually and therefore the peptide bridges must 
be broken (via the enzyme autolysin) in order to allow new peptidoglycan monomers to 
be inserted in the cell wall resulting in cell wall growth and eventually binary fission11. 
Transpeptidases or penicillin binding proteins (PBPs) are the bacterial enzymes 
responsible for cross-linking peptidoglycan monomers forming a rigid cell wall12.   
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Figure 3. Structure of the Gram-positive peptidoglycan and cell wall. Note the penicillin 
bound transpeptidases which result in holes (no peptide cross-bridges) between the 
peptidoglycan monomers.11 
 
 
 
Ampicillin  
 Ampicillin is a -lactam antibiotic from the penicillin family with a mass of 
approximately 349.41 g/mol. Ampicillin differs from penicillin only by the presence of an 
amino group which helps the drug to penetrate the outer membrane of Gram-negative 
bacteria. It is also commonly used to treat infections caused by Gram-positive bacteria, 
those species featuring a cell wall rich in peptidoglycan13. Ampicillin irreversibly binds 
with transpeptidases in the cell wall by forming a highly stable penicilloyl-enzyme 
intermediate11. Autolysin continues to break the peptide bridges in order to allow cell 
wall expansion, but without unbound transpeptidases to fill the holes with new 
 7 
 
peptidoglycan monomers, the cells undergo lysis due to osmotic pressure11. Ampicillin 
effectively inhibits the final stage of bacterial wall synthesis, binary fission, and results in 
cell death. 
 Alterations in the penicillin-binding proteins of bacterial strains are responsible 
in part for the antibiotic resistance demonstrated by some bacteria (E.g. Methicillin 
resistant Staphylococcus aureus or MRSA). These resistant strains will not respond to 
low levels of antibiotic and require a large dosage, in some cases larger than is clinically 
achievable.13  
Summary 
 The treatment of infections caused by exposure to bacterial biofilms has become 
a topic of interest in recents years, especially with the increased usage of plastics in the 
medical field (prostetics, catheters, IVs, artificial hearts, etc.). Recent studies have 
resulted in the development of many theories to account for the antibiotic resistance of 
biofilms, but their proteomic response to drug treatments remains largely 
unstudied3,14,15. 
 The development of in-vitro methods for determining proteomic response across 
a biofilm would provide a useful tool for the medical community in treating biofilm 
related infections. The identification of proteins involved in biofilm response to 
antimicrobial agents would not only enable medical professionals to prescribe more 
effective antibiotics, but it would also allow scientists to develop more efficient drug 
treatments. If the proteins involved in the defense mechanisms of bacterial biofilms 
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could be illucidated, scientists could develop drugs that specifically bind said proteins, 
expediting the irradication of infection. 
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CHAPTER II 
 
TRACKING DRUG DIFFUSION AND PROTEIN CHANGES ACROSS A STAPHYLOCOCCUS 
AUREUS BIOFILM EXPOSED TO AMPICILLIN USING MALDI IMS 
 
Introduction 
 
MALDI Imaging Mass Spectrometry 
 Matrix-assisted laser desorption/ionization or MALDI is defined as the selective 
transduction of photon energy to the desorption of molecules and/or ions from the 
condensed phase resulting in gas phase ions. It features a laser, usually a nitrogen laser, 
which when fired at a sample with an applied matrix solution, produces a plume of ions 
which can then be detected by a mass spectrometer, typically a time-of-flight (TOF) 
instrument.16 
 The matrix consists of crystallized molecules dissolved in a solution of water and 
an organic solvent such as acetonitrile or ethanol. Common matrices include 3,5-
dimethoxy-4-hydroxycinnamic acid (sinapinic acid or SA), α-cyano-4-hydroxycinnamic 
acid (CHCA), and 2,5-dihydroxybenzoic acid (DHB). Selection of a matrix is dependent on 
the analyte of interest. For instance, sinapinic acid is commonly used in the detection of 
proteins whereas DHB is used primarily for lipids. Matrices can either be pre-mixed with 
the sample, or may be spotted manually or mechanically over a sample or onto tissue17. 
The main roles of the matrix are to cocrystallize with the analyte, to absorb incident 
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photon energy from the laser in order to prevent destruction of the sample, and to aid 
in the ionization of the sample analytes18. 
 
 
 
 
Figure 4. Schematic representation of the steps involved in profiling and IMS analysis of 
tissue samples.19  
 
 
 Sample preparation involves the sectioning of either fresh froxen or formalin-
fixed parafin-embedded (FFPE) tissue (typically 5-10 µm in thickness) and mounting on a 
conductive MALDI surface such as a gold plate or ITO coated slide. The sample is washed 
to remove salts and lipids before recieving a coating of matrix and undergoing analysis 
on a mass spectrometer. Ionization of the sample is achieved by firing a laser in an 
ordered pattern across the surface of the sample, ablating material and creating an 
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average spectrum for each spot. Each spot or pixel contains many analyte signals, each 
of which can be individually displayed within the tissue when a false color scale is 
applied to the optical image displaying relative intensity.20  
 MALDI Imaging Mass Spectrometry has gained popularity in recent years due to 
its ability to detect the presence of various biological molecules, most notably proteins 
and drug molecules in tissue21. It has also been successfully utilized in the mapping of 
structural components of various organs and in the discernment of normal versus tumor 
tissue in mice22. Following preparation of a sample, IMS can be used to determine the 
relative abundance and location of proteins, drugs, and metabolites within tissue 
creating a protein map across different regions of the sample23. 
 
Imaging Bacterial Proteins  
 Analysis of bacterial biofilms is typically accomplished through visual 
observations made using electron and optical microscopies or via laser desorption 
postionization mass spectrometry (LDPI-MS). LDPI-MS has previously been used to 
detect peptides within a Bacillis subtilis biofilm as well as to detect the presence of 
rifampicin in a treated Staphylococcus epidermidis biofilm grown on an ITO slide24,25. 
However, this method provides no spatial information regarding the distribution of 
peptides or drug molecules within the sample. 
 Imaging Mass Spectrometry has previously been used to track proteins 
associated with infection in mice infected with S. aureus. Corbin et al. used IMS to image 
calprotectin, a Ca2+ binding protein which inhibits the growth of bacterial pathogens in-
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vivo26. Calprotectin is primarily found in the kidney where staphylococcal abscesses 
form and represents an innate immune response by the body to infection. Recent 
experiments have utilized the same technology to create co-registered three 
dimensional images of calprotectin in an infected mouse kidney.27 
 
 
 
 
Figure 5. Co-registered IMS and MRI images displaying signals associated with 
calprotectin as well as a structural protein27. A) Hematoxylin and eosin stained image 
showing kidney abscesses (denoted by arrows) in an infected animal. B) Blockface image 
showing the same kidney abscesses. C) Coregistered IMS and MRI image of the protein 
mass at m/z 5,020 (cortex specific protein). D) Coregistered IMS and MRI image of the 
protein mass at m/z 10,165 (calprotectin). 
 
 
 Previous studies have also proven IMS to be a useful tool in the analysis of 
bacterial colonies. This technology has been used to image various proteins and 
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metabolic products of bacteria grown on MALDI targets and to track interactions 
between different bacterial colonies including metabolic exchange, the expression of 
cannabalistic factors, and colony-to-colony signaling28.  
Dorrestein et al. utilized IMS in the study of metabolic exchange between 
Bacillus subtilis and Streptomyces coelicolor and determined that B. subtilis inhibits the 
production of secondary metabolites in S. coelicolor. However, other metabolites, 
including prodiginines, were shown to be upregulated in S. coelicolor in the presence of 
B. subtilis.28 
  Additionally, IMS was utilized in the identification of cannabilistic factors in B. 
subtilis. A normal strain was allowed to interact with a mutant strain of the same 
bacteria on nutrient agar. The MALDI data revealed the presence of sporulation killing 
factor (Skf) and sporulation delaying protein (Sdp) in the normal strain, both of which 
were utilized by the bacteria in the cannabalistic killing of the mutant strain.29 
 Imaging Mass Spectrometry can also be applied to the study of biofilms. 
Following the application of a liquid matrix, a biofilm grown on a conductive surface can 
be imaged using MALDI to determine the molecular profile of the biological system. If 
the sample is treated with a drug, such as an antibiotic, tandem mass spectrometry can 
be used to establish distribution of the drug molecule across the film. These images can 
then be compared, in order to determine whether or not molecular descriptors are up 
or down-regulated in the film in response to the drug. 
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Methods and Materials 
 
Materials 
 The MALDI matrices, sinapinic acid, 2,5-dihydroxybenzoic acid, and -cyano-4-
hydroxycinnamic acid as well as the hematoxylin were purchased from Sigma Chemical 
Co. (St. Louis, MO). Acetic acid, ethanol, Xylene, eosin, and ampicillin were purchased 
from Fisher Scientific (Suwanee, GA). Tin oxide coated slides (ITO slides) were purchased 
from Delta Technologies (Stillwater, MN).  
Determining a Proper Matrix 
 Colonies of the Newman strain of Staphylococcus aureus were isolated on a TSB 
agar plate. The bacteria were streaked over the surface of an entire agar plate and 
incubated for 24 hours at 37°C to create a lawn of bacterial growth. Antibiotic (20µL) 
was applied to small round filter papers at concentrations of 100, 10, 1, 0.1, 0.01, and 
0.001 µg/mL. The filter papers were applied to the streaked agar plates in an evenly 
spaced, circular pattern and the plates were placed in an incubator at 37°C overnight. 
Kanamycin, erythromycin, chloramphenocol, ampicillin, and Zyvox were tested. 
 The zone of clearing around the filter papers was observed and measured. Once 
an ideal concentration was determined, the antibiotic was analyzed using various 
matrices in order to determine which allowed for the formation of antibiotic specific 
fragment ions during MALDI MS/MS analysis.  
 Fresh samples of the antibiotic were prepared and 1 µL of the drug was mixed 
with 1 µL of a sinapinic acid matrix at a concentration of 20 mg/mL (in 50:50 acetonitrile 
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and water with 0.1% TFA added). DHB (30 mg/mL) and CHCA (20 mg/mL) were also 
tested. The mixture was spotted on a clean ITO slide for analysis. Pure matrix was 
spotted on the slide for comparison.  
The spots were analyzed on a Thermo Scientific LTQ XL MALDI instrument (LTQ 
20712) to produce both MS and MS/MS spectra. These spectra were compared with the 
results obtained from the pure matrix samples and it was determined that kanamycin 
and ampicillin produced the most intense fragment peaks when mixed with a sinapinic 
acid matrix (Figure 6). 
Sample Preparation  
 Newman strain Staphylococcus aureus biofilms were grown on cut (25x25 mm) 
indium tin oxide (ITO) coated slides. The square slides were soaked in 100% ethanol for 
approximately 5 minutes then drained and exposed to UV light for 2 minutes. The slides 
were run through a flame for sterilization and placed into individual Petri dishes. Each 
slide was streaked with bacteria and 20 mL of TSB broth was added. The dishes were 
placed in an incubator at 37°C for 8 days. The TSB broth was drained and replenished 
daily. 
 Following the 8 day growth period, the TSB broth was drained and the edges of 
the slides were lightly dabbed with a Kim Wipe to wick away excess moisture. The 
biofilms received a small filter paper containing 20 µL of ampicillin at a concentration of 
800 µg/mL in ddH2O. Initial drug imaging experiments using the ideal concentration 
determined for ampicillin (10 µg/mL) failed to detect the antibiotic at that 
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concentration. It appears as though the layered structure of the biofilm may result in 
absorption of the drug deep into the film and so a much higher concentration was 
necessary for imaging of radial drug diffusion.  
After application of the antibiotic, the biofilms were placed back in the incubator 
for 10 hours at 37°C. Following this period of drug exposure, the filter paper was 
removed and the underside of the biofilm cleansed with anhydrous ethyl alcohol, dried, 
and exposed to UV light in a UV Stratalinker 2400 four times at 4000 µJ x 100 of energy. 
The films were placed in a -80°C freezer for storage.  
Samples were spotted on a Portrait 630 Acoustic Robotic Microspotter (Labcyte) 
with a 20 mg/mL sinapinic acid solution (in 50:50 water and acetonitrile solution with 
0.1% TFA added). The samples received matrix in a block pattern (140 columns, 140 
rows) consisting of five drops each pass for a total of six passes with 150 µm spacing. 
The spotted biofilms were scanned using an Epson Perfection 4990 Photo scanner at a 
resolution of 2400 dpi in 16-bit grayscale (Figures 8B and 9B). 
Analysis 
 Drug imaging was performed on a Thermo LTQ XL MALDI instrument, monitoring 
for m/z 350.1 with a collision energy of 27.0 µJ over a mass window from m/z 95.00-
450.00. The imaging was done in positive, profile mode at a laser energy of 15 µJ with 3 
microscans per step, 5 shots per scan, and 10 scans per file. ImageQuest software was 
used to analyze the data (Figures 8A and 9A). 
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 Proteins were imaged using a Bruker Autoflex II Mass Spectrometer over the 
mass window from 800-10,000 Da in 50 shot steps for a total of 400 shots per matrix 
spot with a raster of 150x150 µm. The instrument was run in positive, linear mode with 
the linear voltage set at 3.1 kV, a laser repetition rate of 1000 Hz, ion source voltages of 
19.5 kV (1) and 18.3 kV (2), a delay time of 350 ns, and a lens voltage of 6 kV. 
FlexImaging software was used to analyze the data (Figures 8C-D and 9C-D). 
Determining Biofilm Thickness 
 Samples were cultured using the previously described protocol. Three biofilms 
were taken from storage, thawed, and small portions were scraped away at various 
points using a razor blade. The films were placed on an Olympus BX-50 microscope. 
Using Image Pro-Plus 7.0 software, the etched positions on the film were put into focus 
using an Olympus 150x objective lens for a total magnification of approximately 3151x. 
The bottom or ITO slide surface was set as the Z-bottom. The top or biofilm surface was 
set as the Z-top and the software calculated the difference creating a measurement of 
biofilm thickness in micrometers. This was repeated for 25 individual points across each 
of the three biofilms and the values were averaged (Figure 11). 
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Results 
 
 
Figure 6. A) MALDI MS/MS spectra for m/z 350.1, ampicillin. Note fragment peaks at 
m/z 159.92, 173.92, and 191.0. This spectra represents the data collected for 1 µL of 
ampicillin (10 µg/mL in ddH2O) mixed with 1µL of sinapinic acid (in 50:50 
water:acetonitrile with 0.1% TFA added). Note: when imaging ampicillin on a biofilm the 
first two fragment peaks are shifted to m/z 160.08 and 174.08 respectively most likely 
due to the thickness of the biofilm which affects the conductivity of the ITO surface and 
results in peak shifting. B) MALDI MS/MS spectra for pure sinapinic acid matrix under 
the same conditions. 
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Figure 7. Ampicillin imaging for the mass range [m/z 159.58-160.58 plus m/z 173.58-
174.58] of A) a control, S. aureus biofilm exposed to 20 µL of ddH2O for 10 hours at 37°C 
and B) a S. aureus biofilm exposed to 20 µL of 800 µg/mL of ampicillin for 10 hours at 
37°C. 
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                              m/z 2100                 m/z 2350  
 
                 m/z 3262                 m/z 2346 
 
                m/z 3503           m/z 3092 
 
                 m/z 1785                 m/z 6906 
 
Figure 8. Examples of IMS revealing various proteins/peptides specific to exposure to 
ampicillin in a S. aureus biofilm. A) Drug imaging performed on a Thermo LTQ MALDI 
mass spectrometer over the mass range [m/z 159.58-160.58 plus m/z 173.58-174.58].  
B) Scanned image of the biofilm following application of matrix. C) Protein signals, yet to 
be identified, which are antibiotic specific. D) Protein signals (yet to be identified) 
specific to the areas of the film which have not been exposed to the drug. The mass-to-
charge ratios are given below and intensity scales beside the corresponding images. 
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                m/z 3056         m/z 5530 
 
                m/z 3100               m/z 3060 
 
                m/z 3070               m/z 6910 
 
                m/z 1795          m/z 3060 
 
Figure 9. Examples of IMS revealing various proteins/peptides specific to structural 
components of the S. aureus biofilm. A) Drug imaging performed on a Thermo LTQ 
MALDI mass spectrometer over the mass range [m/z 159.58-160.58 plus m/z 173.58-
174.58]. B) Scanned image of the biofilm following application of matrix. C and D) 
Unidentified proteins specific to structural components indicative of thicker/thinner 
regions of biofilm, differences in the amount of extracellular polysaccharides, etc. The 
mass-to-charge ratios are given below and the intensity scaled beside the corresponding 
images. 
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Figure 10. Example spectra from two S. aureus biofilms exposed to ampicillin. Zoom 
provided for m/z 2600-3600: proteins related to biofilm structure.  
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Figure 11. Determination of the average thickness and the average number of bacterial 
layers present in a S. aureus biofilm treated with ampicillin. A) Measurements made at 
25 individual points for three separate bacterial biofilms resulted in the determination 
of average biofilm thickness. Results for trials 1, 2, and 3 were 40.02, 46.72, and 36.18 
µm with standard deviations of ± 15.69, 18.33, and 10.98 µm respectively. B) 
Approximation of the number of bacterial layers for each trial based on the thickness of 
a single S. aureus bacterium (0.5 µm). Results for trials 1, 2, and 3 were approximately 
80, 93, and 72 layers respectively. 
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Discussion 
 
 Utililizing IMS, the low mass (m/z 800-10,000) molecular profile of 
Staphylococcus aureus Newman Str. biofilms treated with ampicillin was examined and 
compared with drug imaging. Certain signals were more abundant in regions where the 
antibiotic was present (E.g. m/z 1785, 2100, etc.) while others were more abundant in 
areas where the drug was absent (E.g. m/z 2350, 6906, etc.). Several unidentified signals 
showed similar distributions to the drug (Figure 8) indicating that they were produced 
by the bacteria in response to the antibiotic. Molecular descriptors expressed only in 
drug free regions of the biofilm may have been triggered following cell-cell signaling 
from the bacteria that were exposed to the drug and may indicate a preemptive 
response to the oncoming drug treatment. 
 Especially intriguing were the signals that were present in the m/z 2600-3600 
range. These signals were present in every sample analyzed and appear to correspond 
to structural features of the biofilm (Figures 9 and 10). Thicker regions of the biofilm 
contain more cells, resulting in areas that appear to “light up” when false color is 
applied to the image. If denser regions of biofilm could be identified they could be 
specifically targeted before they are able to disperse into the surrounding environment 
resulting in further colonization. This could prove useful in the targeted treatment of 
biofilms on exogenous surfaces such as those prevalent in water treatment facilities. 
 Results published by Bernardo, et. al using MALDI-TOF data collected from 
Staphylococcus aureus MRSA str. bacteria grown on Columbia blood agar and lysed in 50 
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mM sinapinic acid matrix (in acetonitrile/0.1% TFA 70:30 v/v) revealed the same general 
peak patterns observed here. Their spectra displayed the same groupings of signal 
reported here at approximately m/z 2500, 3000, 4500, and 5500 (Figure 10). They also 
reported unidentified signals at m/z 5526, 5567, 6890, and 6927 which were present in 
the samples analyzed in this study.30 
 Measurements of biofilm thickness revealed an average thickness of 40.97 µm 
indicating a biofilm composed of approximately 81 bacterial layers. Results across three 
different samples were relatively consistent (Figure 11) indicating that it is possible to 
grow Staphylococcus aureus biofilms in-vitro reproducibly. The use of a flow cell by 
Jones et. al resulted in a 69 µm thick Staphylococcus aureus MRSA str. biofilm after 2 
days of growth in an artificial urine medium31. Measurements were made using a 
scanning electron microscope. Considering the sample preparation methods utilized 
here, the results reported seem reasonable as one would not expect biofilm adhesion 
and growth to occur as rapidly in a system without moving/flowing medium.  
 The imaging results produced in this experiment suggest that bacterial biofilms 
produce low molecular weight proteins/peptides in response to ampicillin and that the 
cells are likely communicating via cell to cell signaling resulting in the production of 
defensive proteins in areas awaiting antibiotic exposure. Additionally, bacteria exposed 
to the antibiotic treatment may cease production of proteins that are consistently being 
produced by healthy, unexposed bacteria. If we can identify which proteins are being 
produced by the bacteria in an attempt to protect themselves, we could develop 
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methods for blocking their production thereby allowing for more successful treatment. 
Analysis of the high mass proteins involved in the biofilms response would also be useful 
in determing the defensive mechanisms of the bacteria. 
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CHAPTER III 
 
EVALUATING PROTEIN GRADIENTS ACROSS A TREATED STAPHYLOCOCCUS AUREUS 
BIOFILM USING LIQUID CHROMATROGRAPHY TANDEM MASS SPECTROMETRY 
 
Introduction 
 
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) 
 Liquid Chromatography (LC) is a separation technique in which a liquid sample is 
pushed through a solid stationary phase in a packed column by a liquid mobile phase 
resulting in the separation of the chemical components of the sample. Chromatography 
can also be used to remove salts or contaminants as well as to concentrate samples 
prior to analysis.32  
Different types of column packing materials include silica gels bound to various 
compounds such as alumina, size exclusion particles, and ion-exchange resins. The 
mobile phase used to elute the sample components off of the column will depend on 
the stationary phase being used as well as the polarity of the analyte but generally 
consists of methanol, acetonitrile, hexanes, or an organic-water mixture. The pH and 
ionic composition of the mobile phase will determine the analyte’s retention time. Most 
common today are reversed phase (RP) columns which feature a hydrophobic, non-
polar stationary phase, such as C-18, and a polar mobile phase. Reversed phase columns 
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are also commonly packed with silica particles covalently bound to non-polar alkyl 
chains for separations under alkaline conditions.33 
 The measurement of mass-to-charge ratios via mass spectrometry does not 
necessarily result in the unique identification of proteins so additional sample 
preparation and/or analyses are necessary23. Liquid chromatography is used to separate 
the chemical components of a sample before it is ionized and characterized by mass-to-
charge ratios and relative abundance by tandem mass spectrometers34. This technique 
is common in the analysis of urine and blood for illicit drugs and their metabolites as 
well as in the determination of proteins and amino acids in all types of samples from 
homogenized tissue to serum to bacteria. 
Strong Cation Exchange (SCX) Chromatography 
 Ion-exchange chromatography is a separation process in which charged analyte 
ions in flowing solution compete with mobile phase ions for sites with opposing charge 
on a solid stationary phase. Analyte ions that have a high affinity for the ion-exchange 
sites are retained longer than ions that do not compete well with the mobile phase ions 
resulting in varying retention times for the different components of the sample.32 
 The stationary phase may be a naturally occurring compound such as sodium 
aluminosilicate, a clay like montmorillonate, or a synthetic compound such as zirconium 
phosphate. More often, the stationary phase is composed of a resin prepared by 
copolymerization of styrene and divinylbenzene. The copolymerized resin is then 
covalently bound to ionic functional groups35. In the case of strong cation exchangers 
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(SCX), sulfonic acid functional groups are bound to the resin resulting in an anionic 
surface36. Therefore, samples must be acidified prior to separation on a SCX column. 
 Ion-exchange resins are incorporated into high-performance liquid 
chromatography (HPLC) columns either as porous polymer beads or as porous silica 
particles coated in resin. The incorporation method is dependent upon whether the 
resin includes a strong or a weak ion-exchange site and on the extent of cross-linking 
between the divinylbenzene and polystyrene which determines the resin’s permeability. 
Low levels of cross-linking result in larger pore size and more accessible ion-exchange 
sites but the resin will adsorb more water. Conversely, a resin with high levels of cross-
linking will have smaller pores making the ion-exchange sites less accessible to analyte.33 
 Ion-exchange chromatography is common in organic chemistry as well as 
biochemistry. It is generally used to separate metallic ions as well as proteins and amino 
acids. It has also proven to be a useful tool in the structural elucidation of proteins from 
peptide sequences when used in conjunction with tandem mass spectrometry.35 
MudPIT 
 Multidimensional Protein Identification Technology or MudPIT is a non-gel 
technique for the separation and identification of complex protein mixtures from 
peptides. MudPIT consists of a 2-dimensional chromatographic separation followed by 
electrospray/nanospray ionization and sample characterization by mass spectrometry. 
The first dimension is typically a strong cation exchange (SCX) column. The second is an 
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analytical reverse phase (RP) column which serves to separate the peptides in the 
sample and is compatible with electrospray ionization.37 
 
Figure 12. Schematic representation of the basic steps involved in the analysis of a 
complex protein mixture via MudPIT.37  
 
 
 
 Samples are first denatured and the proteins digested using a protease such as 
trypsin before being acidified and injected into the SCX column. Charged peptides bind 
to the ion-exchange sites while uncharged peptides pass through and are trapped on a 
RP trap column. The peptides are then eluted from the trap column onto an analytical 
RP column, separated, eluted, and detected by a mass spectrometer. Salt at a particular 
concentration is then pulsed through the SCX column displacing the bound peptides and 
driving them into the RP trap column. The salt is removed during a wash step and the 
peptides are separated on the analytical RP column for detection via MS. The most 
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intense peptide peaks are selected and fragmented during a second MS scan37.  Peptide 
fragments can then be searched in a database such as SEQUEST to produce protein 
identifications.  
 Specific proteins involved in a bacterial biofilm’s response to antibiotics can also 
be determined via liquid chromatography tandem mass spectrometry (LC-MS/MS) using 
MudPIT. Proteins can be collected from lysed Staphylococcus aureus biofilm cells, 
purified on a gel, digested using trypsin, and analyzed via MudPIT. Proteins can then be 
identified using a database and spectral counts for proteins involved in the bacteria’s 
defensive mechanisms can be determined allowing for relative quantitation of said 
proteins. This method features a much higher dynamic range than what is possible in 
MALDI imaging and thus will be useful in identifying high mass proteins. 
 
Methods and Materials 
 
Materials 
 Acetic acid, ammonium acetate, dithiothreitol (DTT), iodoacetamide (IA), and  
phenylmethylsulfonyl fluoride (PMSF) were purchased from Sigma Chemical Co. (St. 
Louis, MO). The methanol, Ambic, and ethanol were purchased from Fisher Scientific 
(Suwanee, GA). Laminator sheeting was purchased from 3M (St. Paul, MN). Trypsin was 
purchased from Promega (Madison, WI). All chromatography resins were purchased 
from Phenomenex (Torrance, CA). Fused silica columns were purchased from Polymicro 
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Technologies (Phoenix, AZ). Trifluoroacetic acid was purchased from Thermo Scientific 
(Asheville, NC). Formic acid and acetonitrile (with 0.1% formic acid added) were 
purchased from VWR International (Suwanee, GA). Phosphate buffered saline was 
purchased from Mediatech Inc. (Manassas, VA). Lysostaphin was purchased from AMBI 
Products LLC. (Lawrence, NY). 
  
Counting Bacteria  
 LC-MS/MS analyses require a minimum of approximately 1x106 cells for 
adequate detection of proteins so determining the average number of cells per mm2 of 
S. aureus biofilms is imperative. This information was necessary in order to determine 
how large the sample sections needed to be in order to yield viable data. 
 S. aureus biofilms were grown and exposed to antibiotic using the method 
described below (See Sample Preparation). Upon removal from the -80°C freezer, 
samples were warmed to room temperature, and dried under a sterile fume hood. 
Three square portions of biofilm were cut from different regions of the sample. Each 
was placed in an Eppendorf tube and 200 µL of PBS (1x) buffer solution was added. The 
samples were sonicated in an ice bath for 60 minutes, vortexed, and the solution 
pipetted up and down to remove any remaining bacteria from the plastic surface. 
 The 200 µL samples were pipetted into the first three wells of a 100 well plate. 
The samples underwent a 10 fold dilution resulting in a total of 21 dilutions, 7 for each 
of the three squares. Each dilution was spotted (10 µL) onto a dry agar plate and the 
plates were incubated at 37°C overnight. Colony forming units (CFUs) were counted 
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within the highest dilution displaying bacterial growth. A second agar was spotted and 
analyzed using the same dilutions to confirm the results (Table 1). 
Sample Preparation  
 Newman strain Staphylococcus aureus biofilms were grown on cut (25x25 mm) 
plastic laminator sheeting (Scotch). The square slides were soaked in 100% ethanol for 
approximately 5 minutes then drained and exposed to UV light for 1 hour. The slides 
were placed into individual Petri dishes. Each slide was streaked with bacteria and 20 mL 
of TSB broth was added and the dishes were placed in an incubator at 37°C for 8 days. 
The TSB broth was drained and replenished daily. 
 Following the 8 day growth period, the TSB broth was drained and the biofilms 
received a circular piece of filter paper containing 20 µL of ampicillin at a concentration 
of 800 µg/mL in ddH2O. After application of the antibiotic, the biofilms were placed back 
in the incubator for 10 hours. Following this period of drug exposure, the filter paper 
was removed, the underside of the biofilm cleansed with anhydrous ethyl alcohol, and 
the films were placed in a -80°C freezer for storage. 
 The samples were thawed and dried in sterile a hood. A 4 mm wide  strip was cut 
across the center of the film spanning the entire length of the sample. The strip was 
then cut into square sections approximately 4x4 mm in size and each added to a 1.5 mL 
Eppendorf tube. The tubes then received 150 µL of a stock solution composed of 500 µL 
of TM buffer, 7 µL of lysostaphin (an enzyme that effectively breaks the peptide bridges 
linking the NAG and NAM sugars of the peptidoglycan) and 7.5 µL of 
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phenylmethylsulfonyl fluoride (PMSF; a protease inhibitor). The samples were vortexed 
and incubated in a water bath at 37°C for 40 minutes. Occasional vortexing helped the 
bacteria to slough off of the plastic sheeting. At the end of the incubation period the 
plastic sheeting was removed and the samples were sonicated via probe for 
approximately 10 seconds to break open any protoplasts not destroyed by the 
lysostaphin treatment. 
 
  
Figure 13. Schematic showing the general location of each 4x4 mm section cut from a S. 
aureus biofilm for analysis via LC-MS/MS. The red circle denotes the location of the 
antibiotic filter paper (7 mm in diameter). Note: Uneven diffusion of the drug favored 
section 4 over section 3 (Figures 14-17). 
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Short Stack 
 In order to digest the samples for LC-MS/MS analysis using a protease such as 
trypsin, the protease inhibitor (PMSF) used in sample preparation must first be 
removed. The simplest way to do this is to run a short stack.  
 The lysostaphin treated samples received 2.5 µL of NuPage LDS Sample Buffer 
(4x) for every 6.5 µL of sample material. To this solution, dithiothreitol, or DTT, (500 mM 
in ddH2O) reducing agent was added in a 1:10 DTT to sample solution ratio. The samples 
were placed on a heat block at 55°C for 20 minutes. A short stack was run on a NuPage 
10% Bis/Tris gel using MOPS (1x) running buffer, with 500 µL NuPage Antioxidant added 
to the upper (cathode) buffer chamber, at constant 200 V for 5 minutes. The gel was 
removed and placed on a plate shaker in a solution of 50 mL methanol, 10 mL acetic 
acid, and 40 mL Milli-Q water for 10 minutes. The fixing solution was removed and a 
staining solution composed of 55 mL Milli-Q water, 10 mL methanol, and 10 mL of 
Novex Stainer A was added to the sample on the plate shaker for 10 minutes. After 10 
minutes, 5 mL of Novex Stainer B was added and the sample was left on the plate shaker 
for a minimum of 3 hours after which the staining solution was drained and 200 mL of 
Milli-Q water was added. The sample was allowed to destain overnight. 
In-gel Digestion and Extraction 
 The short stacks were excised and added to 1.5 mL Eppendorf tubes. To the 
tubes, 100 mM Ambic solution was added, enough to cover the gels, and the samples 
were allowed to sit for 10 minutes. DTT reducing agent (45 mM) was added in a 1:10 
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DTT to Ambic ratio and  the solution was incubated at 55°C for 20 minutes after which 
Iodoacetamide, or IA, (100 mM) was added in a 1:1 IA to DTT ratio. Due to the light 
sensitivity of IA, the sample was allowed to sit in the dark for 20 minutes. The Ambic, 
DTT, and IA solution was removed via pipette and the sample was treated with a 
solution of 50 mM Ambic with 50% acetonitrile (ACN) (enough to cover the gels) for 15 
minutes to remove the stain. This process was repeated 2-3 times. The destaining 
solution was removed, enough ACN was added to cover the gels, and the samples were 
allowed to sit for 10 minutes. The ACN was removed and the gels were dried via speed 
vac for 5-10 minutes or until dry. 
 The dried samples received enough trypsin (0.01 mg/mL Promega Trypsin Gold 
in acetic acid and 25 mM Ambic) to rehydrate the gels. To the samples, 25 mM Ambic 
was added, enough to cover the rehydrated samples and the tubes were incubated 
overnight at 37°C. The Ambic solution was pipetted off of the gels and added to new 
vials. To the gels, a solution of 60% ACN with 0.1% trifluoroacetic acid (TFA) was added, 
enough to cover the samples. The solution was allowed to sit for 15 minutes and the 
ACN/TFA solution was removed and added to the secondary vials. This extraction was 
repeated a second time and the secondary vials were dried via speed vac for several 
hours. The resulting material was brought up in 50 µL of 0.1% formic acid and acidified 
for MudPIT analyses. 
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Analysis 
  Samples were loaded via pressure injection platform (New Objective, Woburn, 
MA) onto a 150 µm internal diameter, split phase MudPIT column consisting of 3-4 cm 
of Jupiter C-18 (5 µm, 300 Å pore size) and 3-4 cm of Luna SCX resin (5 µm, 100 Å pore 
size) fritted into an M520 filter union (IDEA, Oak Harbor, WA). After loading, the column 
was placed in line with an 18 cm Jupiter (3 µm, 300 Å pore size) 100 µm internal 
diameter, self-packed analytical column. 
 Peptides were resolved using an Eksigent 1D+ HPLC system through a 22 hour 
MudPIT separation with eleven 5 µL salt pulses (25, 50, 75, 100, 150, 200, 250, 300, 500, 
700 mM, 1 M ammonium acetate) followed by an organic gradient (45% ACN with 0.1% 
TFA added; 95% ACN with 0.1% TFA added, on the last salt pulse only) at a flow rate of 
500 nL/min to resolve each eluted set of peptides.  
 Tandem mass spectra were collected data-dependently using a Thermo Finnigan 
LTQ Mass Spectrometer, equipped with a nanoelectrospray source, with a collision 
energy of 35.0 µJ and a source voltage of 2.43 kV. The spectra were searched with 
SEQUEST against a Staphylococcus aureus Newman Str. database. 
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Results 
 
Table 1. Determination of the average number of colony forming units (CFUs) per 
square millimeter of bacterial biofilm. CFUs were counted at the highest dilution visible, 
back calculations resulted in the number of CFUs in 200 µL of the original stock solution, 
and the CFUs present per mm2 of bacterial biofilm were determined. The average 
number of bacteria per square millimeter was calculated to be 5416895 CFU/mm2 OR 
5.42x106 CFU/mm2. 
 
Sample Agar 1: CFU counted in 
lowest dilution: 
CFU in 200 µL stock: CFU/mm2 of material: 
A (Corner) 1x109 CFU/mL 2x108 CFU 11025966 
B (Center) 4x108 CFU/mL 8x107 CFU 3103301 
C (Central edge) 1x108 CFU/mL 2x107 CFU 897062 
Sample Agar 2: CFU counted in 
lowest dilution: 
CFU in 200 µL stock: CFU/mm2 of material: 
A (Corner) 1x109 CFU/mL 2x108 CFU 11025966 
B (Center) 6x108 CFU/mL 1.2x108 CFU 4654951 
C (Central edge) 2x108 CFU/mL 4x107 CFU 1794124 
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Table 2. Summarized results for the defensive proteins identified which display trends 
across the biofilm. Data for the probability of correct protein identification, protein 
percentage of the total spectra, the number of peptides used to identify the protein, the 
number of unique peptides, the number of total spectra, the percentage of amino acids 
identified, and the molecular weight of the protein are given. Peptides for each protein 
and section are given in the appendix. 
Penicillin-Binding Protein 1 
Section Prob %Spec #Pep #Uniq #Spec %Cov Weight 
1 100% 2.49E-05 6 6 6 0.13172042 83 kDa 
2 100% 3.07E-05 7 7 7 0.14784946 83 kDa 
3 100% 3.21E-05 5 5 7 0.088709675 83 kDa 
4 100% 1.30E-05 3 3 3 0.10215054 83 kDa 
5 100% 2.81E-05 6 6 6 0.12768817 83 kDa 
6 100% 2.63E-05 4 4 6 0.1155914 83 kDa 
Penicillin-Binding Protein 2 
Section Prob %Spec #Pep #Uniq #Spec %Cov Weight 
1 100% 9.13E-05 14 17 22 0.2957359 80 kDa 
2 100% 6.14E-05 9 13 14 0.21595599 80 kDa 
3 100% 8.70E-05 12 16 19 0.23796424 80 kDa 
4 100% 9.54E-05 12 15 22 0.2696011 80 kDa 
5 100% 1.13E-04 13 15 24 0.23933975 80 kDa 
6 100% 6.57E-05 9 11 15 0.15543328 80 kDa 
Penicillin-Binding Protein 3 
Section Prob %Spec #Pep #Uniq #Spec %Cov Weight 
1 100% 1.66E-05 4 4 4 0.11866859 77 kDa 
2 100% 2.63E-05 5 5 6 0.083936326 77 kDa 
3 100% 1.83E-05 4 4 4 0.11577424 77 kDa 
4 100% 1.74E-05 4 4 4 0.14037627 77 kDa 
5 100% 1.88E-05 3 3 4 0.060781475 77 kDa 
6 100% 8.76E-06 2 2 2 0.05065123 77 kDa 
Penicillin-Binding Protein 4 
Section Prob %Spec #Pep #Uniq #Spec %Cov Weight 
1 33% 0 0 0 0 0 48 kDa 
2 100% 8.77E-06 2 2 2 0.07424594 48 kDa 
3 100% 9.16E-06 2 2 2 0.10208817 48 kDa 
4 100% 3.04E-05 5 5 7 0.14849187 48 kDa 
5 100% 4.69E-06 1 1 1 0.04408353 48 kDa 
6 100% 0 0 0 0 0 48 kDa 
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Table 2—cont. 
Cell Division Protein FtsQ 
Section Prob %Spec #Pep #Uniq #Spec %Cov Weight 
1 99% 8.30E-06 2 2 2 0.075 50 kDa 
2 100% 1.32E-05 3 3 3 0.06590909 50 kDa 
3 100% 1.83E-05 3 4 4 0.15454546 50 kDa 
4 100% 4.34E-06 1 1 1 0.027272727 50 kDa 
5 100% 3.28E-05 3 4 7 0.08409091 50 kDa 
6 100% 2.63E-05 3 4 6 0.10227273 50 kDa 
General Stress Protein-Like Protein 
Section  Prob %Spec #Pep #Uniq #Spec %Cov Weight 
1 100% 3.24E-04 12 19 78 0.68711656 18 kDa 
2 100% 3.55E-04 9 15 81 0.5705522 18 kDa 
3 100% 3.34E-04 11 13 73 0.68711656 18 kDa 
4 100% 2.95E-04 12 17 68 0.70552146 18 kDa 
5 100% 3.57E-04 12 18 76 0.68711656 18 kDa 
6 100% 4.16E-04 13 17 95 0.70552146 18 kDa 
Methicillin Resistance Expression Factor FemA 
Section Prob %Spec #Pep #Uniq #Spec %Cov Weight 
1 100% 2.08E-04 15 23 50 0.4047619 49 kDa 
2 100% 2.41E-04 17 21 55 0.63095236 49 kDa 
3 100% 1.65E-04 14 18 36 0.43571427 49 kDa 
4 100% 2.86E-04 19 26 66 0.53571427 49 kDa 
5 100% 2.72E-04 15 23 58 0.5285714 49 kDa 
6 100% 2.10E-04 16 23 48 0.4952381 49 kDa 
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Table 3.  LC-MS/MS MudPIT results for sections 1-6 taken from a S. aureus biofilm 
treated with ampicillin. The total number of spectral counts for each section as well as 
the number of proteins identified are reported (Min. # of peptides= 5, 99% protein, 95% 
peptide, 8.3% FDR). Normalized spectral counts for penicillin-binding proteins 1-4, cell 
division protein FtsQ, general stress protein-like protein, and methicillin resistance 
expression factor FemA. 
Section: 1 2 3 4 5 6 
Total Spectral Counts: 240892 227970 218301 230504 213151 228349 
Number of Proteins 
Indentified: 
1086 1087 1087 1088 1088 1086 
Penicillin Binding 
Protein 1 (PBP1) 
5.6422 6.9557 7.2638 2.9483 6.3765 5.9521 
Penicillin Binding 
Protein 2 (PBP2) 
20.6882 13.9114 19.7160 21.6205 25.5062 14.8804 
Penicillin Binding 
Protein 3 (PBP3) 
3.7615 5.9620 4.1507 3.9310 4.2510 1.9840 
Penicillin Binding 
Protein 4 (PBP4) 
0 1.9873 2.0754 6.8793 1.0628 0 
Cell Division Protein 
FtsQ 
1.8807 2.8211 3.7615 0.9404 6.5826 5.6422 
General Stress 
Protein-like Protein 
73.3489 76.1701 68.6471 63.9452 71.4682 89.3352 
Methicillin Resistance 
Expression Factor 
FemA 
47.0186 51.7204 33.8534 62.0645 54.5415 45.1378 
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Figure 14. Plot displaying the normalized spectral counts for each section for penicillin-
binding protein 1 and penicillin-binding protein 4. Note the opposing trends: down-
regulation of penicillin-binding protein 1 in section 4 and up-regulation of penicillin-
binding protein 4 in section 4. See Figure 13 for section positions. 
 
 
 
 
Figure 15. Plot displaying the normalized spectral counts for each section for methicillin 
resistance expression factor FemA and penicillin-binding protein 4. Note the same 
general trends: down-regulation in section 3 and up-regulation in section 4. See Figure 
13 for section positions. 
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Figure 16. Plot displaying the normalized spectral counts for each section for cell 
division protein FtsQ and penicillin-binding protein 1. Note the same general trends: 
down-regulation in section 4 and up-regulation in the adjacent samples, 3 and 5. See 
Figure 13 for section positions. 
 
 
 
 
 
Figure 17. Plot displaying the normalized spectral counts for each section for general 
stress protein-like protein. Notice the down-regulation of this protein in section 4 and 
up-regulation in the other sections (6 especially). See Figure 13 for section positions. 
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Discussion 
 Determination of the number of bacteria per mm2 of bacterial biofilm revealed 
approximately 5.42x106 CFU/mm2 (Table 1).  Previous studies involving Pseudomonas 
aeruginosa biofilms grown on a metal surface for 50 hours revealed 4.0x105 CFU/mm2 
so the measurement presented in this study seems reasonable3. The number of bacteria 
counted in this experiment was sufficient for analyses via LC-MS/MS. 
 Analysis of gradient samples via MudPIT identified approximately 1087 proteins 
for each section of the biofilm including general stress proteins, immunoglobulins, MHC 
receptor proteins, cell division proteins, extracellular matrix and plasma proteins, 
ribosomal proteins, DNA gyrase proteins, and transpeptidases. All four of the 
transpeptidases or penicillin-binding proteins (PBPs) associated with Staphylococcus 
aureus Newman str. were detected.  
There were also a number of stress related proteins present, consistent with 
what one would expect when bacteria are exposed to an antimicrobial drug. There were 
several proteins associated with virulence present as well, including protein A and a 
methicillin resistance factor.  
Spectral counts of penicillin-binding proteins 1 and 4 revealed interesting trends 
across the biofilm. Penicillin-binding protein 1 was relatively consistent in sections 1-3 
but was down-regulated in section 4 whereas penicillin-binding protein 4 was up-
regulated in section 4 (Figure 14). These results are specific to the region of the film 
which received the antibiotic filter paper during sample preparation making these data 
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particularly interesting as they represent the biofilm’s proteomic response to the drug 
treatment.  
PBP 1 is the largest penicillin-binding protein of the four with a mass of 83 kDa 
while PBP 4 is the smallest with a mass of 48 kDa. Antibiotics that function by binding 
transpeptidases in the cell wall of Staphylococcus aureus bacteria specifically bind PBPs 
1, 2, and 3, not PBP 438. In response to the antibiotic treatment, the bacteria increase 
production of PBP 4 which binds ampicillin with very low affinity and whose 
transpeptidase activity can sustain cell growth in susceptible cells38,39. Meanwhile PBP 1 
production slows as it will be bound by the drug in the cell wall38. Note:  Penicillin-
binding proteins 2 and 3 were relatively consistent across all sections and didn’t display 
any significant trends from section to section. 
Intriguingly, there were several other proteins present in the samples which 
showed very similar trends to specific PBPs. For instance, methicillin resistance 
expression factor protein FemA displayed the same general trend as penicillin-binding 
protein 4. Both proteins were up-regulated in section 4 and down-regulated in the 
adjacent section, section 3 (Figure 15). As previously mentioned, antibiotic resistance in 
strains of Staphylococcus aureus in is part the result of alterations in the PBPs of the 
bacteria13. This may account for the heightened levels of methicillin resistance protein 
concurrent with up-regulation of penicillin-binding protein 4.   
Cell division protein FtsQ and penicillin-binding protein 1 displayed the opposite 
trend. Both proteins were down-regulated in section 4 and up-regulated in the adjacent 
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sections, 3 and 5 (Figure 16). This trend may represent cell-to-cell signaling activities as 
the bacteria in section 4 may be warning the adjacent sections of the oncoming 
treatment. These sections then respond, attempting to bolster their immunity by 
increasing cellular density. 
Additionally, methicillin resistance expression factor protein FemA and cell 
division protein FtsQ displayed opposing trends. Cell division protein FtsQ was down-
regulated in section 4 while methicillin resistance expression factor protein FemA was 
up-regulated in 4. This may be a defense mechanism of the bacteria. When exposed to 
an antibiotic such as ampicillin they may put cell division activities aside in order to 
focus their energy on the production of resistance proteins in an attempt to defend 
themselves against the treatment. 
Spectral counts for a general stress protein revealed down-regulation in section 
4 with spikes in the protein at the outer edges of the film, section 6 for example (Figure 
17). It may be that the bacteria in section 4 are dying and thus producing less of this 
protein. Meanwhile, cell-to-cell signaling may result in higher levels of stress protein in 
the unaffected areas of the film as they prepare to defend themselves against the 
oncoming treatment. 
MudPIT analyses identified several proteins involved in the defensive response 
of a S. aureus Newman Str. biofilm to treatment with an antimicrobial drug. Cell division 
protein levels indicate that the bacteria attempt to increase cell density when alerted to 
the presence of an antibiotic. They also produce resistance proteins which may result in 
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the alteration of PBPs making them harder to bind in the cell wall. Some PBPs are up-
regulated in response to the drug while others are down-regulated. Additionally, a few 
proteins show increased concentrations in the film concurrent with specific penicillin-
binding proteins which may indicate symbiotic regulation of said proteins. 
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SYNOPSIS AND CONCLUSIONS 
 
 Imaging Mass Spectrometry allowed for the mapping of low mass proteins which 
were triggered in response to treatment with the antibiotic ampicillin. Images 
corresponding to individual mass-to-charge ratios indicated the presence of proteins 
which are up-regulated in response to the antibiotic, proteins triggered by cell-to-cell 
signaling, as well as proteins representative of structural components of the biofilm. 
Identification of additional, higher mass proteins via liquid-chromatography 
tandem mass spectrometry revealed numerous proteins involved in the biofilm’s 
defensive response to the treatment. These included stress proteins, resistance factors, 
transpeptidases or penicillin-binding proteins, as well as cell division proteins.  
Cell division proteins were down-regulated in the section exposed to the largest 
dosage of antibiotic (section 4) and up-regulated in the surrounding sections indicating 
that the biofilm attempts to increase cell density when threatened with an antimicrobial 
drug. General stress proteins were also down-regulated in section 4, which may be 
indicative of cell death, but up-regulated in the surrounding regions. Both of these 
responses may be the result of cell-to-cell signaling.  
Resistance factors were heightened in the affected section. This may represent 
the bacteria’s last effort to survive the treatment. Penicillin-binding proteins 1 and 4 
shared the same general trends as cell division protein FtsQ and methicillin resistance 
expression factor FemA respectively, which may point to a symbiotic relationship 
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between the proteins. Penicillin-binding proteins 2 and 3 levels were relatively 
consistent from section to section. 
 Biofilms grown in-vitro represent a better model for the study of infection in the 
human body as the biological system more closely resembles bacterial infections 
resulting from indwelling medical devices than do single layer colonies grown on an agar 
surface. Their unique structure, resulting in inherent antibiotic resistance, makes the 
treatment of infections resulting from bacterial biofilms very difficult. Further study of 
protein response and cell-to-cell signaling utilizing this method may shed light on how 
biofilms respond to various antimicrobial drugs and could help medical professionals 
develop more effective treatments. 
 Future work should involve the treatment and imaging of an infected animal 
treated with ampicillin to compare proteomic profiles in order to determine the extent 
to which these in-vitro models can be used in the study of biofilm related infections. 
Recent studies have already utilized Imaging Mass Spectrometry as a tool in the 3-
dimensional mapping of infection and inflammatory response to infection across an 
entire animal27.  
Additional samples would help to confirm the LC-MS/MS results obtained here. 
Conducting these experiments using an antibiotic with a different mechanism of action 
such as kanamycin or Zyvox would also be very interesting as the proteomic response 
should involve a different set of defensive proteins.  
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Studies involving biofilms composed of several types of bacteria would be more 
informative as biofilm related infections are generally composed of multiple strains 
and/or species of bacteria. Furthermore, the use of a flow cell in these in-vitro models 
may allow us to further studies of biofilm growth, the development of antibiotic 
resistance, and to better mimic biological conditions inside the body.  
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Penicillin-Binding Protein 1 
Section Sequence Prob SEQUEST XCorr deltaCn NTT Modifications 
1 
(K)DLFAVVmDAKTGEILAYSQRPTFNPETGK(D) 95% 2.1823 0.2881 2 Oxidation (+16) 
(R)GKIYDRNGKVLAEDVERYK(L) 95% 2.1688 0.334 2 
 
(K)GSGFVSHQSISK(G) 95% 1.7448 0.3966 2 
 
(K)PRHVVDKKETAKK(L) 95% 2.0958 0.2289 1 
 
(K)PRHVVDKKETAKKLSTVINMKPEEIEK(R) 95% 2.2605 0.3172 1 
 
(K)YLVKNAQQPERGKIYDRNGKVLAEDVERYK(L) 95% 2.5173 0.2662 2 
 
2 
(K)AFKPImENTLK(Y) 95% 1.69 0.3232 2 Oxidation (+16) 
(K)DLFAVVmDAKTGEILAYSQRPTFNPETGK(D) 95% 2.0552 0.3089 2 Oxidation (+16) 
(R)FYPNGNFASHLIGRAQK(N) 95% 2.5079 0.1692 2 
 
(K)GPNPYFVSFMGDAPK(K) 95% 2.2454 0.317 2 
 
(K)GSGFVSHQSISK(G) 95% 2.8141 0.5052 2  
(K)LVAVIDKKASANSKKPRHVVDK(K) 95% 2.43 0.2214 2 
 
(K)TGEILAYSQRPTFNPETGKDFGK(K) 95% 4.9078 0.5698 2 
 
3 
(K)GPNPYFVSFMGDAPK(K) 95% 1.8428 0.3264 2 
 
(K)GPNPYFVSFmGDAPK(K) 95% 3.1107 0.4181 2 Oxidation (+16) 
(K)GSGFVSHQSISK(G) 95% 2.6705 0.4364 2 
 
(R)HVVDKKETAKKLSTVINMK(P) 95% 2.2636 0.3553 1 
 
(R)HVVDKKETAKKLSTVINmKPEEIEK(R) 95% 2.026 0.2143 2 Oxidation (+16) 
(R)HVVDKKETAKKLSTVINmKPEEIEK(R) 95% 2.5926 0.386 2 Oxidation (+16) 
(R)YIHDIWGYIAPNTK(K) 95% 4.5403 0.5753 2 
 
 
4 
 
(K)AIDNVSAKSLEPVTIGSGTQIK(A) 95% 2.3826 0.2046 2 
 
(K)DLFAVVmDAKTGEILAYSQRPTFNPETGK(D) 95% 2.3871 0.4207 2 Oxidation (+16) 
(R)HVVDKKETAKKLSTVINmKPEEIEK(R) 95% 2.5638 0.2506 2 Oxidation (+16) 
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5 
(K)GPNPYFVSFMGDAPK(K) 95% 2.9499 0.5744 2 
 
(K)GSGFVSHQSISK(G) 95% 2.9704 0.4743 2 
 
(K)IFDSYLSGSK(G) 95% 2.4501 0.2979 2 
 
(K)IYDRNGKVLAEDVERYKLVAVIDKK(A) 95% 2.313 0.2036 2 
 
(K)TGEILAYSQRPTFNPETGK(D) 95% 2.3256 0.3632 2 
 
(R)YQPKDLFAVVMDAKTGEILAYSQR(P) 95% 2.4193 0.2646 1 
 
6 
(K)ASANSKKPRHVVDKKETAKK(L) 95% 2.329 0.1973 2 
 
(K)ASANSKKPRHVVDKKETAKK(L) 95% 1.9077 0.2592 2 
 
(K)ASANSKKPRHVVDKKETAKK(L) 95% 2.2374 0.2622 2 
 
(R)FYPNGNFASHLIGRAQK(N) 95% 2.5523 0.1649 2 
 
(K)IDVEFSSENVDSNSTNNSDSNSDDKK(K) 95% 3.0831 0.1832 2 
 
(K)TGEILAYSQRPTFNPETGKDFGK(K) 95% 4.2587 0.4493 2 
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Penicillin-Binding Protein 2 
Section Sequence Prob SEQUEST XCorr deltaCn NTT Modifications 
1 
(K)AFKDENLGNVLQSGIK(I) 95% 3.9971 0.2397 2 
 
(K)DAVLATEDNR(F) 95% 2.0345 0.3377 2 
 
(R)DFKDVVNR(N) 95% 2.0174 0.327 2 
 
(R)FYEHGALDYKR(L) 95% 2.4799 0.317 2 
 
(R)KAQEAYLSYR(L) 95% 2.3743 0.3288 2 
 
(R)KAQEAYLSYR(L) 95% 2.6786 0.3894 2 
 
(R)LEQEYSKDDIFQVYLNK(I) 95% 4.976 0.2729 2 
 
(R)LEQEYSKDDIFQVYLNK(I) 95% 4.3073 0.5397 2 
 
(K)NLTGGFGSEGASTLTQQVVK(D) 95% 5.1489 0.5227 2 
 
(K)NLTGGFGSEGASTLTQQVVK(D) 95% 4.3904 0.5888 2 
 
(K)PFLAYGPAIENMK(W) 95% 3.3031 0.376 1 
 
(R)QSFNIPALK(A) 95% 1.9132 0.2714 2 
 
(K)QYGENSFVGHSQQEYPQFLYENVMSK(I) 95% 3.2361 0.3589 2 
 
(K)RPSSVSGSIPSINVSGSQDNNTTNR(S) 95% 3.7415 0.297 2 
 
(K)RPSSVSGSIPSINVSGSQDNNTTNR(S) 95% 3.0814 0.3918 2 
 
(K)RPSSVSGSIPSINVSGSQDNNTTNR(S) 95% 4.0485 0.4092 2 
 
(K)SHGTVSIYDALR(Q) 95% 3.0243 0.5103 2 
 
(K)SHGTVSIYDALR(Q) 95% 3.0792 0.6966 2 
 
(K)TGGLVAISGGR(D) 95% 2.4689 0.5055 2 
 
(K)TGGLVAISGGR(D) 95% 2.7145 0.5464 2 
 
(K)TLQNDVDNGSFYKNKDQQVGATILDSK(T) 95% 2.0425 0.2655 2 
 
(K)TLQNDVDNGSFYKNKDQQVGATILDSK(T) 95% 2.6911 0.2436 2 
 
2 (K)AFKDENLGNVLQSGIK(I) 95% 2.89 0.4581 2 
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2 
(R)FYEHGALDYKR(L) 95% 2.7986 0.5002 2 
 
(R)FYEHGALDYKR(L) 95% 3.2648 0.513 2 
 
(R)FYEHGALDYKR(L) 95% 2.3663 0.5264 2 
 
(R)HEHVNLK(D) 95% 1.8346 0.3456 2 
 
(R)HEHVNLK(D) 95% 2.6965 0.2614 2 
 
(R)LEQEYSKDDIFQVYLNK(I) 95% 2.52 0.1948 2 
 
(-)MTENKGSSQPKKNGNNGGKSNSKKNR(N) 95% 2.2742 0.248 2 
 
(K)NLTGGFGSEGASTLTQQVVK(D) 95% 4.9786 0.5382 2 
 
(K)RPSSVSGSIPSINVSGSQDNNTTNR(S) 95% 4.4151 0.5772 2 
 
(K)RPSSVSGSIPSINVSGSQDNNTTNR(S) 95% 5.1951 0.7026 2 
 
(K)SHGTVSIYDALR(Q) 95% 3.0322 0.4375 2 
 
(K)SHGTVSIYDALR(Q) 95% 3.5649 0.6387 2 
 
(R)STHGGSDTSANSSGTAQSNNNTR(S) 95% 4.0098 0.3719 2 
 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
(K)AFKDENLGNVLQSGIK(I) 95% 4.6048 0.2601 2 
 (K)AFKDENLGNVLQSGIK(I) 95% 4.3484 0.5594 2 
 (R)FYEHGALDYKR(L) 95% 2.5794 0.3948 2 
 (R)FYEHGALDYKR(L) 95% 2.666 0.5424 2 
 (R)HEHVNLK(D) 95% 2.0998 0.2841 2 
 (R)KAQEAYLSYR(L) 95% 2.7855 0.4024 2 
 (R)KAQEAYLSYR(L) 95% 2.377 0.5481 2 
 (K)KFAAK(L) 95% 1.2656 0.3277 2 
 (R)LEQEYSKDDIFQVYLNK(I) 95% 3.6555 0.1931 2 
 (K)NLTGGFGSEGASTLTQQVVK(D) 95% 5.3321 0.5767 2 
 (K)QYGENSFVGHSQQEYPQFLYENVMSK(I) 95% 3.7658 0.2981 2 
 (K)RPSSVSGSIPSINVSGSQDNNTTNR(S) 95% 2.3815 0.4074 2 
 (K)RPSSVSGSIPSINVSGSQDNNTTNR(S) 95% 3.7974 0.421 2 
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(K)RPSSVSGSIPSINVSGSQDNNTTNR(S) 95% 4.66 0.49 2 
 (K)SHGTVSIYDALR(Q) 95% 3.1208 0.5218 2 
 (K)SHGTVSIYDALR(Q) 95% 2.8545 0.4602 2 
 (K)SHGTVSIYDALR(Q) 95% 3.2371 0.6995 2 
 (K)SMKDAVLATEDNRFYEHGALDYKR(L) 95% 2.1961 0.2641 2 
 (K)TGGLVAISGGR(D) 95% 2.782 0.5178 2 
  
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
(K)AFKDENLGNVLQSGIK(I) 95% 4.6313 0.5158 2 
 (K)AFKDENLGNVLQSGIK(I) 95% 4.5227 0.5248 2 
 (K)AMSDYTAYMLAEMLK(G) 95% 2.943 0.4744 2 
 (K)AWQSVKQNAGNDAPK(K) 95% 2.555 0.2519 2 
 (K)DAVLATEDNR(F) 95% 2.1279 0.4495 2 
 
(R)DGETIEYDHTSHKAmSDYTAYmLAEmLKGTFK(P) 95% 2.4696 0.2272 1 
Oxidation (+16), 
Oxidation (+16), 
Oxidation (+16) 
(R)HEHVNLK(D) 95% 2.2521 0.1987 2 
 (K)NLTGGFGSEGASTLTQQVVK(D) 95% 5.1864 0.5799 2 
 (K)RPSSVSGSIPSINVSGSQDNNTTNR(S) 95% 5.2425 0.6902 2 
 (K)RPSSVSGSIPSINVSGSQDNNTTNR(S) 95% 6.0911 0.6026 2 
 (K)RPSSVSGSIPSINVSGSQDNNTTNR(S) 95% 5.4526 0.6486 2 
 (K)SHGTVSIYDALR(Q) 95% 1.8799 0.2626 2 
 (K)SHGTVSIYDALR(Q) 95% 3.0028 0.5968 2 
 (K)SHGTVSIYDALR(Q) 95% 3.0474 0.6219 2 
 (K)SHGTVSIYDALR(Q) 95% 3.4992 0.4302 2 
 (K)TGGLVAISGGR(D) 95% 2.1907 0.3137 2 
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4 
 
 
 
(K)TGGLVAISGGR(D) 95% 2.3287 0.2756 2 
 (K)TGGLVAISGGR(D) 95% 2.4378 0.487 2 
 (K)TGGLVAISGGR(D) 95% 3.2734 0.5209 2 
 (K)TLQNDVDNGSFYKNKDQQVGATILDSK(T) 95% 2.06 0.2624 2 
 (K)TLQNDVDNGSFYKNKDQQVGATILDSK(T) 95% 2.8214 0.2873 2 
 (K)WATNHAIQDESSYQVDGSTFR(N) 95% 3.2166 0.4965 2 
  
 
 
 
 
 
 
 
 
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
(K)AFKDENLGNVLQSGIK(I) 95% 3.4165 0.2712 2 
 
(K)AFKDENLGNVLQSGIK(I) 95% 4.3766 0.5348 2 
 
(K)AFKDENLGNVLQSGIKIYTNMDKDVQK(T) 95% 2.6732 0.2625 2 
 
(K)AQEAYLSYR(L) 95% 2.4816 0.4725 2 
 
(R)DGETIEYDHTSHKAmSDYTAYmLAEmLKGTFK(P) 95% 2.2442 0.2588 1 
Oxidation (+16), 
Oxidation (+16), 
Oxidation (+16) 
(R)FYEHGALDYKR(L) 95% 2.9056 0.6091 2 
 
(R)HEHVNLK(D) 95% 1.8094 0.2957 2 
 
(R)ITDKQWEDAK(K) 95% 3.3178 0.3955 2 
 
(R)KAQEAYLSYR(L) 95% 1.5131 0.4106 2 
 
(R)KAQEAYLSYR(L) 95% 2.2253 0.4214 2 
 
(K)NLTGGFGSEGASTLTQQVVK(D) 95% 5.2712 0.5522 2 
 
(K)NLTGGFGSEGASTLTQQVVK(D) 95% 4.8228 0.5795 2 
 
(R)QSFNIPALK(A) 95% 2.0095 0.2518 2 
 
(R)QSFNIPALK(A) 95% 1.8556 0.3261 2 
 
(K)RPSSVSGSIPSINVSGSQDNNTTNR(S) 95% 4.1082 0.4471 2 
 
(K)RPSSVSGSIPSINVSGSQDNNTTNR(S) 95% 4.23 0.6529 2 
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5 
 
(K)SHGTVSIYDALR(Q) 95% 2.6681 0.3092 2 
 
(K)SHGTVSIYDALR(Q) 95% 3.1631 0.643 2 
 
(K)SHGTVSIYDALR(Q) 95% 3.6949 0.6629 2 
 
(K)SHGTVSIYDALR(Q) 95% 3.6203 0.6066 2 
 
(K)TGGLVAISGGR(D) 95% 2.6429 0.3135 2 
 
(K)TGGLVAISGGR(D) 95% 3.5654 0.6082 2 
 
(K)TGGLVAISGGR(D) 95% 3.7845 0.5713 2 
 
(K)TGGLVAISGGR(D) 95% 4.3807 0.6155 2 
 
 
 
 
 
 
 
 
 
 
 
6 
 
 
 
 
 
 
 
 
(K)AFKDENLGNVLQSGIK(I) 95% 2.6575 0.6178 2 
 
(K)AFKDENLGNVLQSGIK(I) 95% 3.9371 0.5585 2 
 
(K)AFKDENLGNVLQSGIK(I) 95% 4.5466 0.5363 2 
 
(R)FYEHGALDYK(R) 95% 2.0233 0.3007 2 
 
(R)KAQEAYLSYR(L) 95% 2.1706 0.3414 2 
 
(R)KAQEAYLSYR(L) 95% 2.2542 0.418 2 
 
(K)KFAAK(L) 95% 1.3664 0.2856 2 
 
(K)NKDQQVGATILDSK(T) 95% 2.3149 0.2453 2 
 
(K)NKDQQVGATILDSK(T) 95% 2.8519 0.4297 2 
 
(K)SHGTVSIYDALR(Q) 95% 1.975 0.2701 2 
 
(K)SHGTVSIYDALR(Q) 95% 3.6895 0.6466 2 
 
(K)TGGLVAISGGR(D) 95% 3.2119 0.6052 2 
 
(K)TGGLVAISGGR(D) 95% 2.3836 0.3996 2 
 
(K)TGTGTYGAETYSQYNLPDNAAK(D) 95% 3.4564 0.616 2 
 
(K)TLQNDVDNGSFYKNKDQQVGATILDSK(T) 95% 2.0152 0.2612 2 
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Penicillin-Binding Protein 3 
Section Sequence Prob SEQUEST XCorr deltaCn NTT Modifications 
1 
(K)KKEmKYTTDKSGKVTSSEVLNPGARGQDLK(L) 95% 2.5557 0.3309 2 Oxidation (+16) 
(K)LRSQGAKDMDNAMMVVQNPKNGDILALAGK(Q) 95% 2.3243 0.2 2 
 
(K)NGHVTINDKQALmHSSNVYMFK(T) 95% 1.8657 0.2269 2 Oxidation (+16) 
(K)QALmHSSNVYmFK(T) 95% 2.0652 0.2649 2 
Oxidation (+16), 
Oxidation (+16) 
2 
(K)DFWIQLHPK(K) 95% 2.5049 0.384 2  
(K)DFWIQLHPK(K) 95% 2.3288 0.4462 2 
 
(K)EVEALLDKQIKK(L) 95% 1.7484 0.2944 2 
 
(K)EVEALLDKQIKKLR(S) 95% 2.1752 0.2947 2 
 
(K)LPGVNTSMDWDR(K) 95% 2.1217 0.3959 2 
 
(K)QDQYDKQLLSKIGKSQLDELSSK(D) 95% 2.3066 0.2499 2 
 
3 
(R)GRILDRNGKVLVDNASKMAITYTR(G) 95% 2.953 0.2099 2 
 
(R)GRKTTQSEmLDTAEKLSKLIKMDTK(K) 95% 2.4685 0.2707 2 Oxidation (+16) 
(K)LIKMDTKKITERDKKDFWIQLHPKK(A) 95% 2.322 0.2214 2 
 
(K)QALMHSSNVYMFK(T) 95% 2.7335 0.4246 2 
 
 
 
 
4 
 
 
(R)EmNAGTVLDPQMIKNEDVSEKEYAAVSQQLSK(L) 95% 2.673 0.1712 2 Oxidation (+16) 
(K)KKEmKYTTDKSGKVTSSEVLNPGARGQDLK(L) 95% 2.4367 0.3262 2 Oxidation (+16) 
(K)KLRSQGAKDMDNAMMVVQNPK(N) 95% 2.2067 0.3294 2 
 
(R)SYFNKNGHVTINDK(Q) 95% 2.2733 0.2707 2 
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5 
 
 
 
 
(K)EVEALLDKQIKKLRSQGAKDmDNAmmVVQNPK(N) 95% 2.8804 0.3051 2 
Oxidation (+16), 
Oxidation (+16), 
Oxidation (+16) 
(R)GLNQVGLGVK(T) 95% 2.4442 0.1575 2 
 
(R)GLNQVGLGVK(T) 95% 2.713 0.465 2 
 
(R)SQGAKDmDNAMMVVQNPK(N) 95% 2.7337 0.2561 2 Oxidation (+16) 
6 
(R)GIFGDVSTPAEGIPK(E) 95% 2.7251 0.576 2 
 
(K)LRSQGAKDmDNAmmVVQNPK(N) 95% 2.1206 0.3419 2 
Oxidation (+16), 
Oxidation (+16), 
Oxidation (+16) 
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Penicillin-Binding Protein 4 
Section Sequence Prob SEQUEST XCorr deltaCn NTT Modifications 
1/6 N/A N/A N/A N/A N/A N/A 
2 
(K)NLGGEKQRNmMGNALmER(S) 95% 2.0926 0.3035 2 
Oxidation (+16), 
Oxidation (+16) 
(K)NTSDFVDLMNNKAK(A) 95% 2.0318 0.2849 2 
 
3 
(K)QLAPTTHAVTYYTFNFSLEGAKmSLPGTDGLK(T) 95% 2.4255 0.2208 2 Oxidation (+16) 
(K)QRNMmGNALmER(S) 95% 1.4838 0.2685 2 
Oxidation (+16), 
Oxidation (+16) 
4 
(K)FRINQVImGAGDYK(N) 95% 1.658 0.3189 2 Oxidation (+16) 
(K)FRINQVImGAGDYK(N) 95% 1.6015 0.3077 2 Oxidation (+16) 
(R)INQVIMGAGDYKNLGGEKQRNMmGNALMER(S) 95% 2.4228 0.2584 2 Oxidation (+16) 
(K)KDYKLVVEDGKVHADYPR(E) 95% 2.2314 0.262 2 
 
(K)KDYKLVVEDGKVHADYPR(E) 95% 1.8306 0.3567 2 
 
(K)NTHFVNPTGAENSR(L) 95% 3.4573 0.53 2 
 
(K)QRNmmGNALmER(S) 95% 2.0245 0.2613 2 
Oxidation (+16), 
Oxidation (+16), 
Oxidation (+16) 
5 (K)NTSDFVDLmNNKAKAIGmK(N) 95% 2.5706 0.2365 2 
Oxidation (+16), 
Oxidation (+16) 
A
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Cell Division Protein FtsQ 
Section Sequence Prob SEQUEST XCorr deltaCn NTT Modifications 
1 
(K)GTKEDDmIKALSEMTPEVRR(Y) 95% 2.4394 0.2263 2 Oxidation (+16) 
(R)YIAEVTYAPSKNK(Q) 95% 2.8196 0.1912 2 
 
2 
(K)IAHVNINGNNHVSTSK(I) 95% 3.2144 0.4338 2 
 
(K)VTQLKPLTLEEK(R) 95% 3.1207 0.4846 2 
 
(K)VTQLKPLTLEEKR(K) 95% 2.7935 0.2427 2 
 
3 
(R)GNTSSQSESDKNVTKSSQEENQAK(E) 95% 2.6702 0.2265 2 
 
(-)mmDDKTKNDQQESNEDKDELELFTRNTSKKRR(Q) 95% 2.6108 0.2437 2 
Oxidation (+16), 
Oxidation (+16) 
(K)VTQLKPLTLEEK(R) 95% 3.2762 0.4324 2 
 
(K)VTQLKPLTLEEK(R) 95% 3.0908 0.5543 2 
 
4 (K)VTQLKPLTLEEK(R) 95% 3.5649 0.5112 2 
 
5 
(K)NAINDLEENPLIK(S) 95% 2.6124 0.4154 2 
 
(R)RYIAEVTYAPSK(N) 95% 2.2899 0.3547 2 
 
(K)VTQLKPLTLEEK(R) 95% 2.4866 0.3546 2 
 
(K)VTQLKPLTLEEK(R) 95% 3.3815 0.3854 2 
 
(K)VTQLKPLTLEEK(R) 95% 3.1244 0.4071 2 
 
(K)VTQLKPLTLEEK(R) 95% 2.2242 0.4142 2 
 
(K)VTQLKPLTLEEK(R) 95% 3.5877 0.5939 2 
 
 
 
6 
 
(K)GKYLPLLENGKLLK(G) 95% 3.8404 0.2848 2 
 
(K)IAHVNINGNNHVSTSKINK(V) 95% 2.0412 0.3803 2 
 
(K)VTQLKPLTLEEK(R) 95% 3.2794 0.3296 2 
 
(K)VTQLKPLTLEEK(R) 95% 3.305 0.475 2 
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6 
 
(K)VTQLKPLTLEEK(R) 95% 2.8442 0.5506 2 
 
(K)VTQLKPLTLEEK(R) 95% 3.3587 0.5463 2 
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General Stress Protein-Like Protein 
Section Sequence 
Pro
b 
SEQUEST XCorr deltaCn NTT Modifications 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(K)ANNVATDANHSYTSR(V) 95% 1.6932 0.2969 2 
 
(K)ANNVATDANHSYTSR(V) 95% 2.2438 0.4337 2 
 
(K)ANNVATDANHSYTSR(V) 95% 3.1471 0.5257 2 
 
(K)ANNVATDANHSYTSR(V) 95% 2.8133 0.6563 2 
 
(K)ANNVATDANHSYTSR(V) 95% 4.8066 0.6056 2 
 
(K)ANNVATDANHSYTSR(V) 95% 5.112 0.6512 2 
 
(K)ANNVATDANHSYTSR(V) 95% 5.3561 0.7208 2  
(R)ETTDLLHK(V) 95% 1.7845 0.3186 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 2.9893 0.2814 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 3.4548 0.5593 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 4.2424 0.5513 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 4.4229 0.5699 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 4.6063 0.6499 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.6843 0.0973 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.028 0.3282 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.5639 0.2789 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.3006 0.3989 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.531 0.3001 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.2944 0.3077 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.4266 0.4318 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.77 0.3045 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.5796 0.3381 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.9098 0.3839 2 
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(K)ISQVVQWSNVAmEIADK(W) 95% 2.7885 0.4646 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.4968 0.3984 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.571 0.5122 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.8169 0.5713 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.497 0.5536 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.0526 0.578 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.4758 0.5077 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.6886 0.5998 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.1643 0.5985 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.7858 0.6019 2 
 
(K)ISQVVQWSNVAmEIADK(W) 95% 4.5594 0.6213 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.402 0.6367 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.5813 0.6439 2 
 
(K)ISQVVQWSNVAmEIADK(W) 95% 5.1295 0.6438 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADK(W) 95% 5.0359 0.6247 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.3584 0.6731 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.267 0.6679 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 2.6033 0.2593 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 2.6801 0.2143 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 2.6886 0.2851 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.8675 0.2829 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.9977 0.512 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.762 0.464 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 3.4759 0.6355 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 4.3385 0.5084 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 4.8308 0.6489 2 Oxidation (+16) 
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(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 4.5204 0.5966 2 
 
(R)LNSVVDAVK(G) 95% 1.463 0.2285 2 
 
(R)LNSVVDAVK(G) 95% 2.8091 0.3322 2 
 
(R)LTEDIQGK(V) 95% 1.7342 0.27 2 
 
(R)LTEDIQGK(V) 95% 2.3842 0.3608 2 
 
(R)LTEDIQGK(V) 95% 1.9973 0.333 2 
 
(K)NLDYVAK(T) 95% 1.6584 0.2949 2 
 
(K)NLDYVAK(T) 95% 1.5706 0.3377 2 
 
(K)NLDYVAKTLDGVEGQVQGITR(E) 95% 2.1871 0.2541 2 
 
(K)TLDGVEGQVQGITR(E) 95% 3.218 0.3371 2 
 
(K)TLDGVEGQVQGITR(E) 95% 3.2202 0.313 2 
 
(K)TLDGVEGQVQGITR(E) 95% 3.0016 0.4789 2 
 
(K)TLDGVEGQVQGITR(E) 95% 4.3721 0.4195 2 
 
(K)TLDGVEGQVQGITR(E) 95% 4.9002 0.3502 2 
 
(R)VTNSITHNISQNEDK(I) 95% 2.399 0.2648 2 
 
(R)VTNSITHNISQNEDK(I) 95% 2.4583 0.2715 2 
 
(R)VTNSITHNISQNEDK(I) 95% 3.3814 0.4161 2 
 
(R)VTNSITHNISQNEDK(I) 95% 3.7033 0.4525 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.4687 0.4698 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.5814 0.5742 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.9 0.5962 2 
 
(R)VTNSITHNISQNEDK(I) 95% 5.2939 0.5672 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.3672 0.6541 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.7476 0.6272 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.9785 0.6255 2 
 
(R)VTNSITHNISQNEDK(I) 95% 3.935 0.5513 2 
 
 6
6
 
 
 
 
1 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 5.485 0.593 2 Oxidation (+16) 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 5.8382 0.621 2 Oxidation (+16) 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 6.4424 0.6404 2 Oxidation (+16) 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
(R)ETTDLLHK(V) 95% 1.7999 0.2777 2 
 
(R)ETTDLLHK(V) 95% 1.8672 0.3071 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 4.0132 0.595 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 2.7324 0.4032 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 3.3507 0.5846 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 4.1832 0.6325 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.2218 0.3411 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.1388 0.2657 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.8137 0.2047 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.7191 0.2504 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.3537 0.3195 2 
 
(K)ISQVVQWSNVAmEIADK(W) 95% 2.8217 0.4405 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.719 0.3835 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.2178 0.4061 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.7536 0.4031 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.9909 0.4531 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.4351 0.3576 2 
 
(K)ISQVVQWSNVAmEIADK(W) 95% 2.8786 0.4988 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.8388 0.4416 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.8734 0.5054 2 
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(K)ISQVVQWSNVAMEIADK(W) 95% 4.5161 0.3895 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.958 0.533 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.5346 0.5722 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.473 0.5589 2 
 
(K)ISQVVQWSNVAmEIADK(W) 95% 4.4817 0.5681 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADK(W) 95% 4.0391 0.6285 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.525 0.6358 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.7674 0.6242 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.0968 0.6153 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.8132 0.6704 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.6263 0.6332 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.2612 0.6796 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 1.914 0.3627 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 2.9743 0.2143 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 2.981 0.248 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 2.4068 0.284 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 3.1216 0.2897 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 2.7257 0.3581 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.1655 0.3591 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 2.997 0.3682 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 3.5988 0.3718 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 2.8635 0.4198 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 3.4104 0.4003 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 2.9479 0.5046 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.2427 0.5314 2 Oxidation (+16) 
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(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 2.8082 0.5933 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.365 0.4185 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 3.6589 0.4661 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 3.4383 0.4648 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 3.9034 0.464 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 5.1092 0.6231 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 4.4421 0.514 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 5.6259 0.6726 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 5.2273 0.6724 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 4.7841 0.6903 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 4.6441 0.5382 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 5.7308 0.6635 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 5.0592 0.5612 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 4.1874 0.5732 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 5.81 0.6997 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 4.8426 0.7335 2 
 
(R)LTEDIQGK(V) 95% 2.1872 0.4047 2 
 
(R)LTEDIQGK(V) 95% 2.5865 0.4184 2 
 
(K)TLDGVEGQVQGITR(E) 95% 2.8351 0.323 2 
 
(K)TLDGVEGQVQGITR(E) 95% 3.6433 0.3781 2 
 
(K)TLDGVEGQVQGITR(E) 95% 3.9793 0.3916 2 
 
(K)TLDGVEGQVQGITR(E) 95% 3.9664 0.4358 2 
 
(K)TLDGVEGQVQGITR(E) 95% 4.8177 0.4443 2 
 
(K)TLDGVEGQVQGITR(E) 95% 4.5955 0.4519 2 
 
(K)VDRLNSVVDAVK(G) 95% 3.0741 0.4017 2 
 
(K)VDRLNSVVDAVK(G) 95% 3.0426 0.3874 2 
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(R)VTNSITHNISQNEDK(I) 95% 3.1493 0.6628 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.0067 0.4975 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.4107 0.5817 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.7651 0.6294 2 
 
(R)VTNSITHNISQNEDK(I) 95% 3.8745 0.5572 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAMEIADK(W) 95% 5.4695 0.4391 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 5.9555 0.6041 2 Oxidation (+16) 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 5.6555 0.6192 2 Oxidation (+16) 
(R)VTNSITHNISQNEDKISQVVQWSNVAMEIADK(W) 95% 6.519 0.6129 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 6.4345 0.6465 2 Oxidation (+16) 
 
 
 
 
 
 
3 
 
 
 
 
 
 
(K)ANNVATDANHSYTSR(V) 95% 3.2158 0.4596 2 
 
(K)ANNVATDANHSYTSR(V) 95% 3.6471 0.5122 2 
 
(R)ETTDLLHK(V) 95% 1.7748 0.2356 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 2.3062 0.4486 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 3.2572 0.4913 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 4.6423 0.6442 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 3.9254 0.6463 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 4.9319 0.6277 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.4074 0.259 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.7994 0.0927 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.7811 0.1606 2 
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(K)ISQVVQWSNVAMEIADK(W) 95% 2.6276 0.4383 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.1997 0.2828 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.2416 0.315 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.8047 0.3336 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.955 0.515 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.2818 0.49 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.5689 0.4653 2 
 
(K)ISQVVQWSNVAmEIADK(W) 95% 3.6685 0.4211 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.3157 0.3899 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.0915 0.4382 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.9359 0.5073 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.9255 0.5396 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.8844 0.468 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.397 0.4458 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.824 0.5149 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.1702 0.6046 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.2907 0.5907 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.5076 0.5826 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.2733 0.6101 2 
 
(K)ISQVVQWSNVAmEIADK(W) 95% 5.0497 0.5579 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADK(W) 95% 4.5947 0.6458 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.8919 0.6247 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.2527 0.6424 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.5708 0.6516 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.7721 0.656 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.57 0.6615 2 
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(K)ISQVVQWSNVAmEIADK(W) 95% 5.3686 0.6467 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 2.1178 0.2438 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 2.6819 0.2528 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 2.4689 0.4141 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.1986 0.3838 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.4168 0.3827 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 4.6367 0.4504 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 4.0325 0.542 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.5084 0.4878 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.9163 0.5329 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 5.2621 0.6534 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 3.7158 0.5475 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 5.4664 0.6637 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 4.4086 0.5792 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 5.1878 0.7127 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.8072 0.6051 2 Oxidation (+16) 
(R)LNSVVDAVK(G) 95% 1.4176 0.2351 2 
 
(R)LNSVVDAVK(G) 95% 3.0781 0.3585 2 
 
(R)LNSVVDAVK(G) 95% 3.1226 0.4116 2 
 
(R)LTEDIQGK(V) 95% 2.0358 0.3829 2 
 
(K)NLDYVAK(T) 95% 1.7945 0.3272 2 
 
(K)TLDGVEGQVQGITR(E) 95% 2.3239 0.2809 2 
 
(K)TLDGVEGQVQGITR(E) 95% 2.76 0.364 2 
 
(K)TLDGVEGQVQGITR(E) 95% 3.0162 0.3375 2 
 
(K)TLDGVEGQVQGITR(E) 95% 4.1329 0.3889 2 
 
(K)TLDGVEGQVQGITR(E) 95% 4.0754 0.3866 2 
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(K)TLDGVEGQVQGITR(E) 95% 4.2171 0.4365 2 
 
(R)VTNSITHNISQNEDK(I) 95% 3.5123 0.4319 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.3083 0.5172 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.6416 0.5788 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAMEIADK(W) 95% 3.7585 0.3579 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAMEIADK(W) 95% 4.2254 0.3434 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAMEIADK(W) 95% 5.693 0.4311 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 4.7312 0.558 2 Oxidation (+16) 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 5.8973 0.6146 2 Oxidation (+16) 
(R)VTNSITHNISQNEDKISQVVQWSNVAMEIADK(W) 95% 6.4812 0.6585 2 
 
 
 
 
 
 
4 
 
 
 
 
 
 
(K)ANNVATDANHSYTSR(V) 95% 3.382 0.4443 2 
 
(K)ANNVATDANHSYTSR(V) 95% 4.8366 0.6263 2 
 
(K)ANNVATDANHSYTSR(V) 95% 4.8074 0.7403 2 
 
(K)ANNVATDANHSYTSR(V) 95% 5.2736 0.7187 2 
 
(R)ETTDLLHK(V) 95% 1.7917 0.3304 2 
 
(R)ETTDLLHK(V) 95% 1.829 0.2869 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 3.108 0.3062 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 3.237 0.5983 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 2.8698 0.4718 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 4.5826 0.6451 2 
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(K)GIGDSVQTLNSSVDR(V) 95% 4.6022 0.6495 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.4822 0.2717 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.5831 0.3923 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.262 0.2926 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.9915 0.416 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.7823 0.4668 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.2595 0.4321 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.3505 0.4896 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.5072 0.4661 2 
 
(K)ISQVVQWSNVAmEIADK(W) 95% 3.6559 0.5637 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.6143 0.633 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.7814 0.6041 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.8274 0.6237 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.4941 0.635 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.4447 0.634 2 
 
(K)ISQVVQWSNVAmEIADK(W) 95% 4.8135 0.6213 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.9137 0.6538 2 
 
(K)ISQVVQWSNVAmEIADK(W) 95% 5.4404 0.664 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.3777 0.6562 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.6637 0.728 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 2.5378 0.2628 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 2.5074 0.3755 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.1378 0.3527 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.2972 0.3512 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 3.262 0.3538 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.1151 0.4645 2 Oxidation (+16) 
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(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 3.7536 0.4239 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 3.3454 0.4669 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 5.4876 0.6236 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 5.3769 0.6447 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 5.1133 0.6625 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 4.9527 0.6458 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 4.0814 0.7271 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 5.0776 0.6902 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 5.0793 0.7204 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 4.2089 0.6237 2 Oxidation (+16) 
(R)LTEDIQGK(V) 95% 2.2871 0.3396 2 
 
(K)NLDYVAK(T) 95% 1.6865 0.2676 2 
 
(K)NLDYVAKTLDGVEGQVQGITR(E) 95% 2.3553 0.4175 2 
 
(K)TLDGVEGQVQGITR(E) 95% 3.0946 0.2913 2 
 
(K)TLDGVEGQVQGITR(E) 95% 3.1264 0.2755 2 
 
(K)TLDGVEGQVQGITR(E) 95% 2.9898 0.401 2 
 
(K)TLDGVEGQVQGITR(E) 95% 4.6766 0.3901 2 
 
(K)TLDGVEGQVQGITR(E) 95% 4.7364 0.4256 2 
 
(K)VDRLNSVVDAVK(G) 95% 2.791 0.3353 2 
 
(R)VTNSITHNISQNEDK(I) 95% 1.6031 0.2792 2 
 
(R)VTNSITHNISQNEDK(I) 95% 0.9332 0.4837 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.3597 0.4998 2 
 
(R)VTNSITHNISQNEDK(I) 95% 3.3289 0.3616 2 
 
(R)VTNSITHNISQNEDK(I) 95% 5.3487 0.6017 2 
 
(R)VTNSITHNISQNEDK(I) 95% 5.2158 0.5753 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.7465 0.6064 2 
 
 7
5
 
 
 
 
 
 
 
4 
 
(R)VTNSITHNISQNEDK(I) 95% 4.8085 0.6002 2 
 
(R)VTNSITHNISQNEDK(I) 95% 3.6594 0.528 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAMEIADK(W) 95% 3.1344 0.3202 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAMEIADK(W) 95% 5.4021 0.5301 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 5.1745 0.5581 2 Oxidation (+16) 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 6.2906 0.623 2 Oxidation (+16) 
 
 
 
 
 
 
 
 
 
5 
 
 
 
 
 
 
 
 
 
(K)ANNVATDANHSYTSR(V) 95% 1.7882 0.544 2 
 
(K)ANNVATDANHSYTSR(V) 95% 3.3959 0.4327 2 
 
(R)ETTDLLHK(V) 95% 1.7645 0.3172 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 2.3134 0.3745 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 3.9132 0.5229 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 1.6587 0.5144 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 3.9835 0.5392 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 4.6744 0.635 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 4.1418 0.6137 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.8223 0.1251 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.4691 0.3783 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.4625 0.3191 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.0183 0.3369 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.6431 0.2696 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.3894 0.5051 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.7622 0.2982 2 
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(K)ISQVVQWSNVAMEIADK(W) 95% 2.6389 0.496 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.2104 0.3745 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.5982 0.3991 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.6853 0.3656 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.6329 0.4368 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.9834 0.357 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.9096 0.441 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.0278 0.4588 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.5568 0.5089 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.9144 0.4651 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.8401 0.5152 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.4131 0.5434 2 
 
(K)ISQVVQWSNVAmEIADK(W) 95% 4.281 0.5622 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.1281 0.5287 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.3751 0.506 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.5828 0.5392 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.5049 0.5421 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.9612 0.646 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.3237 0.6272 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.0741 0.6502 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.9663 0.6914 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.4998 0.6615 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.4174 0.6619 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.861 0.6752 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 2.8815 0.2557 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.2472 0.3415 2 Oxidation (+16) 
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(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.3524 0.3753 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 2.6084 0.5647 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 3.0665 0.4094 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 4.7059 0.49 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 4.2007 0.5281 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 3.8011 0.544 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 5.1683 0.6808 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 5.2941 0.7156 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 5.5624 0.7068 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 5.7129 0.7061 2 
 
(R)LNSVVDAVK(G) 95% 2.9592 0.3224 2 
 
(R)LTEDIQGK(V) 95% 2.1741 0.3804 2 
 
(R)LTEDIQGK(V) 95% 1.9536 0.3625 2 
 
(R)RGSANYKANNVATDANHSYTSR(V) 95% 2.4992 0.2334 2 
 
(K)TLDGVEGQVQGITR(E) 95% 2.6033 0.4153 2 
 
(K)TLDGVEGQVQGITR(E) 95% 1.2389 0.4146 2 
 
(K)TLDGVEGQVQGITR(E) 95% 2.9704 0.2989 2 
 
(K)TLDGVEGQVQGITR(E) 95% 3.4425 0.3435 2 
 
(K)TLDGVEGQVQGITR(E) 95% 3.8166 0.3147 2 
 
(K)TLDGVEGQVQGITR(E) 95% 2.9686 0.4048 2 
 
(K)TLDGVEGQVQGITR(E) 95% 4.5739 0.3278 2 
 
(K)TLDGVEGQVQGITR(E) 95% 3.5888 0.4237 2 
 
(K)TLDGVEGQVQGITR(E) 95% 4.6791 0.4013 2 
 
(K)TLDGVEGQVQGITR(E) 95% 4.0725 0.4952 2 
 
(R)VTNSITHNISQNEDK(I) 95% 2.7091 0.3534 2 
 
(R)VTNSITHNISQNEDK(I) 95% 2.1205 0.3624 2 
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(R)VTNSITHNISQNEDK(I) 95% 4.9047 0.619 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAMEIADK(W) 95% 4.3503 0.409 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 5.9493 0.5822 2 Oxidation (+16) 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 5.9375 0.5792 2 Oxidation (+16) 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 5.6929 0.6263 2 Oxidation (+16) 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 5.5903 0.6404 2 Oxidation (+16) 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 6.2527 0.6843 2 Oxidation (+16) 
(R)VTNSITHNISQNEDKISQVVQWSNVAMEIADKWQNR
(H) 
95% 4.8587 0.3337 2 
 
 
 
 
 
 
6 
 
 
 
 
 
(K)ANNVATDANHSYTSR(V) 95% 2.3282 0.2516 2 
 
(K)ANNVATDANHSYTSR(V) 95% 2.4581 0.4267 2 
 
(K)ANNVATDANHSYTSR(V) 95% 3.5413 0.4065 2 
 
(K)ANNVATDANHSYTSR(V) 95% 2.9564 0.5339 2 
 
(K)ANNVATDANHSYTSR(V) 95% 5.0252 0.6155 2 
 
(K)ANNVATDANHSYTSR(V) 95% 4.9875 0.6517 2 
 
(K)ANNVATDANHSYTSR(V) 95% 5.033 0.6783 2 
 
(K)ANNVATDANHSYTSR(V) 95% 5.1954 0.6763 2 
 
(K)ANNVATDANHSYTSR(V) 95% 5.1219 0.6961 2 
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(R)ETTDLLHK(V) 95% 1.7994 0.3248 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 2.3883 0.3556 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 2.4136 0.4182 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 3.6829 0.5949 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 4.3851 0.5838 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 5.0123 0.6221 2 
 
(K)GIGDSVQTLNSSVDR(V) 95% 4.3 0.6579 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.1789 0.3148 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.5591 0.2964 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 2.2417 0.3293 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.0719 0.3314 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.1617 0.2523 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.3958 0.342 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.8619 0.3177 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.3407 0.3112 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.075 0.4422 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.3542 0.4607 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.2696 0.4526 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.4493 0.5162 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.6872 0.5006 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.3452 0.4747 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.6218 0.4822 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.1884 0.5092 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 3.8183 0.5598 2 
 
(K)ISQVVQWSNVAmEIADK(W) 95% 3.5529 0.6072 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADK(W) 95% 4.8325 0.6194 2 Oxidation (+16) 
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6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(K)ISQVVQWSNVAmEIADK(W) 95% 5.3473 0.6241 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.0518 0.6491 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 4.3126 0.7017 2 
 
(K)ISQVVQWSNVAMEIADK(W) 95% 5.5007 0.7203 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 2.8616 0.1853 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 2.4745 0.2503 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 2.5623 0.2432 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 2.4695 0.277 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.0691 0.2668 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 2.7196 0.3269 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 3.1886 0.3155 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 2.5921 0.3552 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.2431 0.3778 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.2713 0.376 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.3895 0.4206 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.3045 0.4809 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 4.0761 0.455 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 3.6765 0.4955 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 4.0985 0.4854 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 3.9723 0.5439 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 5.1293 0.6655 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 5.0301 0.6439 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 4.3167 0.6866 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 5.3057 0.6681 2 Oxidation (+16) 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 5.0894 0.6721 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 4.9284 0.6956 2 
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(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 5.187 0.7033 2 
 
(K)ISQVVQWSNVAmEIADKWQNR(H) 95% 4.0283 0.564 2 Oxidation (+16) 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 5.4924 0.6723 2 
 
(K)ISQVVQWSNVAMEIADKWQNR(H) 95% 5.0728 0.6806 2 
 
(R)LNSVVDAVK(G) 95% 1.4542 0.2739 2 
 
(R)LTEDIQGK(V) 95% 1.8689 0.2602 2 
 
(R)LTEDIQGK(V) 95% 1.8955 0.2929 2 
 
(R)LTEDIQGK(V) 95% 2.1145 0.4086 2 
 
(K)NLDYVAK(T) 95% 1.4611 0.2695 2 
 
(K)NLDYVAK(T) 95% 1.5472 0.3792 2 
 
(K)NLDYVAKTLDGVEGQVQGITR(E) 95% 2.3276 0.4596 2 
 
(K)TLDGVEGQVQGITR(E) 95% 1.0217 0.4273 2 
 
(K)TLDGVEGQVQGITR(E) 95% 4.3081 0.4198 2 
 
(K)TLDGVEGQVQGITR(E) 95% 4.3726 0.4093 2 
 
(K)TLDGVEGQVQGITR(E) 95% 4.023 0.4127 2 
 
(K)TLDGVEGQVQGITR(E) 95% 4.6807 0.4383 2 
 
(K)TLDGVEGQVQGITR(E) 95% 4.4344 0.4325 2 
 
(K)VDRLNSVVDAVK(G) 95% 2.2623 0.3173 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.6148 0.5565 2 
 
(R)VTNSITHNISQNEDK(I) 95% 3.363 0.4248 2 
 
(R)VTNSITHNISQNEDK(I) 95% 3.4746 0.5581 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.8608 0.581 2 
 
(R)VTNSITHNISQNEDK(I) 95% 5.2243 0.5777 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.8595 0.6028 2 
 
(R)VTNSITHNISQNEDK(I) 95% 5.0252 0.601 2 
 
(R)VTNSITHNISQNEDK(I) 95% 4.9771 0.608 2 
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(R)VTNSITHNISQNEDK(I) 95% 5.0668 0.6178 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAMEIADK(W) 95% 3.7601 0.1931 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAMEIADK(W) 95% 4.8302 0.5104 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 5.3874 0.5721 2 Oxidation (+16) 
(R)VTNSITHNISQNEDKISQVVQWSNVAMEIADK(W) 95% 6.1001 0.5826 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAMEIADK(W) 95% 6.5811 0.6141 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAMEIADK(W) 95% 7.2682 0.6208 2 
 
(R)VTNSITHNISQNEDKISQVVQWSNVAmEIADK(W) 95% 6.0701 0.6217 2 Oxidation (+16) 
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Methicillin Resistance Expression Factor FemA 
Section Sequence Prob SEQUEST XCorr deltaCn NTT Modifications 
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(K)AFADRDDKFYYNR(L) 95% 3.6801 0.4099 2 
 
(K)AFADRDDKFYYNR(L) 95% 2.9211 0.4972 2 
 
(R)FLSEEELPIFR(S) 95% 2.5821 0.2967 2 
 
(R)FLSEEELPIFR(S) 95% 2.457 0.4214 2 
 
(K)FTEDAEDAGVVK(F) 95% 2.0653 0.4072 2 
 
(K)FTEDAEDAGVVK(F) 95% 3.366 0.576 2 
 
(K)FTNLTAK(E) 95% 1.4527 0.2425 2  
(K)FTNLTAK(E) 95% 1.7554 0.3917 2 
 
(K)FTNLTAK(E) 95% 1.4743 0.3357 2 
 
(K)GFDPVLQIR(Y) 95% 1.4639 0.3015 2 
 
(K)GFDPVLQIR(Y) 95% 2.6719 0.4474 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 2.5002 0.369 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.9416 0.5127 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.6544 0.4333 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.3533 0.4895 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.7493 0.4192 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.7009 0.4668 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.9556 0.4678 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.1744 0.6204 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.4204 0.588 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.4029 0.6074 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 5.011 0.6427 2 
 
(K)GYNAEIIEYVGDFIK(P) 95% 2.3717 0.3942 1 
 
A
P
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EN
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(K)LAEGYETHLVGIK(N) 95% 2.1942 0.3274 2 
 
(K)LAEGYETHLVGIK(N) 95% 2.5798 0.3497 2 
 
(K)LAEGYETHLVGIK(N) 95% 2.8663 0.4825 2 
 
(K)LAEGYETHLVGIK(N) 95% 3.1862 0.5564 2 
 
(K)LAEGYETHLVGIK(N) 95% 3.9769 0.607 2 
 
(K)NNNNEVIAAcLLTAVPVmK(V) 95% 2.7783 0.444 2 
Carbamidomethyl 
(+57), Oxidation 
(+16) 
(K)NNNNEVIAAcLLTAVPVMK(V) 95% 4.4751 0.6618 2 
Carbamidomethyl 
(+57) 
(K)NNNNEVIAAcLLTAVPVMK(V) 95% 5.198 0.6663 2 
Carbamidomethyl 
(+57) 
(R)SFMEDTSESK(A) 95% 2.98 0.526 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 2.1637 0.4058 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.7607 0.5432 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.4194 0.5681 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.1299 0.584 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 4.4665 0.5973 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.7071 0.6168 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.9496 0.6376 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 5.6657 0.5093 2 
 
(K)YFYSNR(G) 95% 1.7188 0.2977 2 
 
(R)YHSVLDLK(D) 95% 2.7725 0.3038 2 
 
(R)YHSVLDLK(D) 95% 2.1593 0.3874 2 
 
(R)YHSVLDLK(D) 95% 2.6836 0.339 2 
 
(R)YHSVLDLK(D) 95% 2.6355 0.3715 2 
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(R)YHSVLDLK(D) 95% 2.6481 0.4437 2 
 
(R)YHSVLDLKDK(T) 95% 2.9712 0.2809 2 
 
(R)YHSVLDLKDK(T) 95% 2.8534 0.3419 2 
 
(R)YNFYGVSGK(F) 95% 2.1597 0.3348 2 
 
(R)YNFYGVSGK(F) 95% 2.579 0.2915 2 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
(R)cLYLHIDPYLPYQYLNHDGEITGNAGNDWFFDK(M) 95% 4.9604 0.4881 2 
Carbamidomethyl 
(+57) 
(R)cLYLHIDPYLPYQYLNHDGEITGNAGNDWFFDK(M) 95% 5.6683 0.5716 2 
Carbamidomethyl 
(+57) 
(K)DKTADDIIKNmDGLR(K) 95% 1.486 0.2648 2 Oxidation (+16) 
(K)DKTADDIIKNmDGLR(K) 95% 2.0558 0.2306 2 Oxidation (+16) 
(R)DNLQQQLDANEQK(I) 95% 4.8525 0.5674 2 
 
(K)EFGAFTDSMPYSHFTQTVGHYELK(L) 95% 2.1348 0.1951 2 
 
(K)EFGAFTDSmPYSHFTQTVGHYELK(L) 95% 3.4357 0.3462 2 Oxidation (+16) 
(K)EFGAFTDSMPYSHFTQTVGHYELK(L) 95% 3.1482 0.4419 2 
 
(K)EFGAFTDSMPYSHFTQTVGHYELK(L) 95% 3.6986 0.5801 2 
 
(K)EFGAFTDSmPYSHFTQTVGHYELK(L) 95% 3.6818 0.466 2 Oxidation (+16) 
(K)EFGAFTDSMPYSHFTQTVGHYELK(L) 95% 3.2711 0.6005 2 
 
(K)EFGAFTDSmPYSHFTQTVGHYELK(L) 95% 3.066 0.6581 2 Oxidation (+16) 
(K)EFGAFTDSmPYSHFTQTVGHYELK(L) 95% 3.3541 0.6738 2 Oxidation (+16) 
(K)EFGAFTDSmPYSHFTQTVGHYELK(L) 95% 3.6779 0.6655 2 Oxidation (+16) 
(K)EFGAFTDSMPYSHFTQTVGHYELK(L) 95% 3.941 0.644 2 
 
(R)FLSEEELPIFR(S) 95% 3.3434 0.4481 2 
 
(K)FTEDAEDAGVVK(F) 95% 3.6556 0.5552 2 
 
(K)GFDPVLQIR(Y) 95% 2.1558 0.3908 2 
 
(K)GFDPVLQIR(Y) 95% 2.6538 0.4621 2 
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(R)GPVIDYENQELVHFFFNELSK(Y) 95% 2.8833 0.3578 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 2.5109 0.4298 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.0011 0.4059 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.3627 0.4296 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.8485 0.5275 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.0203 0.6072 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.9642 0.569 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.823 0.6109 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.1175 0.6153 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.7188 0.6453 2 
 
(K)GYNAEIIEYVGDFIKPINKPVYAAYTALK(K) 95% 2.6584 0.2757 2 
 
(K)GYNAEIIEYVGDFIKPINKPVYAAYTALK(K) 95% 3.1766 0.2956 2 
 
(K)GYNAEIIEYVGDFIKPINKPVYAAYTALK(K) 95% 3.0553 0.3406 2 
 
(K)GYNAEIIEYVGDFIKPINKPVYAAYTALK(K) 95% 3.3628 0.3698 2 
 
(R)LQEEHGNELPISAGFFFINPFEVVYYAGGTSNAFR(H) 95% 5.1463 0.6439 2 
 
(R)LQEEHGNELPISAGFFFINPFEVVYYAGGTSNAFR(H) 95% 5.4601 0.6627 2 
 
(R)LQEEHGNELPISAGFFFINPFEVVYYAGGTSNAFR(H) 95% 5.8179 0.6656 2 
 
(K)NNNNEVIAAcLLTAVPVMK(V) 95% 5.1904 0.6139 2 
Carbamidomethyl 
(+57) 
(K)NNNNEVIAAcLLTAVPVmK(V) 95% 5.3714 0.6972 2 
Carbamidomethyl 
(+57), Oxidation 
(+16) 
(K)RPENKKAHNKR(D) 95% 2.3491 0.2663 2 
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2 
 
(K)RPENKKAHNKR(D) 95% 2.4444 0.3147 2 
 
(R)SFMEDTSESK(A) 95% 2.9611 0.4574 2 
 
(K)TADDIIK(N) 95% 1.6403 0.1862 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.2386 0.449 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 2.5745 0.5102 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 2.7703 0.5246 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.0678 0.537 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.0654 0.5516 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.8311 0.5749 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 4.1383 0.6544 2 
 
(R)YHSVLDLK(D) 95% 2.7586 0.3014 2 
 
(R)YHSVLDLK(D) 95% 2.1599 0.3408 2 
 
(R)YHSVLDLK(D) 95% 2.594 0.3888 2 
 
(R)YHSVLDLKDK(T) 95% 3.1783 0.2026 2 
 
(R)YHSVLDLKDK(T) 95% 3.175 0.1957 2 
 
(R)YHSVLDLKDK(T) 95% 3.2204 0.334 2 
 
 
 
 
 
 
3 
 
 
 
 
 
 
(K)AFADRDDKFYYNR(L) 95% 2.8198 0.3435 2 
 
(R)DILNKDLNKALKDIEKRPENK(K) 95% 2.6758 0.2435 2 
 
(K)EFGAFTDSMPYSHFTQTVGHYELK(L) 95% 3.5262 0.6173 2 
 
(K)FTEDAEDAGVVK(F) 95% 3.3968 0.1995 2 
 
(K)FTEDAEDAGVVK(F) 95% 3.4317 0.4834 2 
 
(K)GFDPVLQIR(Y) 95% 2.3464 0.3602 2 
 
(K)GFDPVLQIR(Y) 95% 2.4475 0.4496 2 
 
(K)GFDPVLQIR(Y) 95% 2.4586 0.4676 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.4057 0.4343 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.1382 0.5473 2 
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(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.9973 0.5943 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.9595 0.5722 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.361 0.6052 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.8252 0.585 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.7963 0.6287 2 
 
(K)LAEGYETHLVGIK(N) 95% 4.0566 0.5588 2 
 
(K)LAEGYETHLVGIK(N) 95% 3.6034 0.5628 2 
 
(K)NNNNEVIAAcLLTAVPVmK(V) 95% 3.1047 0.4449 2 
Carbamidomethyl 
(+57), Oxidation 
(+16) 
(K)NNNNEVIAAcLLTAVPVMK(V) 95% 5.6852 0.6614 2 
Carbamidomethyl 
(+57) 
(R)SFMEDTSESK(A) 95% 3.2099 0.435 2 
 
(K)TADDIIK(N) 95% 1.8398 0.2487 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.1494 0.492 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.2263 0.61 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.5314 0.5801 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 4.1606 0.5975 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 4.2587 0.5777 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.999 0.6302 2 
 
(R)YHSVLDLK(D) 95% 2.8819 0.3296 2 
 
(R)YHSVLDLK(D) 95% 2.7474 0.259 2 
 
(R)YHSVLDLK(D) 95% 2.3374 0.3272 2 
 
(R)YHSVLDLK(D) 95% 2.608 0.44 2 
 
(R)YHSVLDLK(D) 95% 2.4222 0.4121 2 
 
(R)YHSVLDLKDK(T) 95% 2.8193 0.1289 2 
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3 
(R)YHSVLDLKDK(T) 95% 2.6737 0.3742 2 
 
(R)YNFYGVSGK(F) 95% 2.3811 0.4708 2 
 
(R)YNFYGVSGK(F) 95% 2.4428 0.4147 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(K)AFADRDDKFYYNR(L) 95% 2.6609 0.3324 2 
 
(K)AFADRDDKFYYNR(L) 95% 3.2954 0.3728 2 
 
(K)DKTADDIIK(N) 95% 1.9979 0.367 2 
 
(K)EFGAFTDSmPYSHFTQTVGHYELK(L) 95% 2.883 0.2016 2 Oxidation (+16) 
(K)EFGAFTDSMPYSHFTQTVGHYELK(L) 95% 2.6429 0.2106 2 
 
(K)EFGAFTDSmPYSHFTQTVGHYELK(L) 95% 2.6328 0.2342 2 Oxidation (+16) 
(K)EFGAFTDSmPYSHFTQTVGHYELK(L) 95% 3.0369 0.4198 2 Oxidation (+16) 
(K)EFGAFTDSMPYSHFTQTVGHYELK(L) 95% 2.9496 0.4296 2 
 
(K)EFGAFTDSMPYSHFTQTVGHYELK(L) 95% 3.3198 0.5568 2 
 
(K)EFGAFTDSmPYSHFTQTVGHYELK(L) 95% 3.4939 0.6152 2 Oxidation (+16) 
(K)EFGAFTDSmPYSHFTQTVGHYELK(L) 95% 3.3684 0.6631 2 Oxidation (+16) 
(K)ELNEERDILNK(D) 95% 3.8304 0.2806 2 
 
(R)FLSEEELPIFR(S) 95% 2.7851 0.378 2 
 
(R)FLSEEELPIFR(S) 95% 2.4963 0.4163 2 
 
(K)FTEDAEDAGVVK(F) 95% 1.9959 0.3554 2 
 
(K)FTEDAEDAGVVK(F) 95% 3.5358 0.6532 2 
 
(K)FTNLTAK(E) 95% 1.2302 0.2692 2 
 
(K)FTNLTAK(E) 95% 1.5787 0.3538 2 
 
(K)GFDPVLQIR(Y) 95% 2.4967 0.3163 2 
 
(K)GFDPVLQIR(Y) 95% 2.2507 0.3845 2 
 
(K)GFDPVLQIR(Y) 95% 2.1413 0.4036 2 
 
(K)GFDPVLQIR(Y) 95% 2.2844 0.3904 2 
 
(K)GFDPVLQIR(Y) 95% 2.9538 0.3921 2 
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(K)GFDPVLQIR(Y) 95% 2.5997 0.4461 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 2.8412 0.2401 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 2.4667 0.3131 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.3666 0.3424 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 2.7831 0.4242 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.9852 0.4634 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.8669 0.4886 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.5689 0.4267 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.2907 0.4896 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.0903 0.574 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.9814 0.593 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.5542 0.5676 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.9852 0.5869 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.1655 0.6354 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.9709 0.7031 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.4741 0.6637 2 
 
(K)GYNAEIIEYVGDFIKPINKPVYAAYTALK(K) 95% 2.7481 0.2927 2 
 
(K)LAEGYETHLVGIK(N) 95% 1.9918 0.2948 2 
 
(K)LAEGYETHLVGIK(N) 95% 1.9897 0.4241 2 
 
(K)LAEGYETHLVGIK(N) 95% 3.696 0.5184 2 
 
(K)LAEGYETHLVGIK(N) 95% 3.9148 0.5356 2 
 
(K)NmDGLRKRNTKK(V) 95% 2.4187 0.2219 2 Oxidation (+16) 
(K)NNNNEVIAAcLLTAVPVMK(V) 95% 4.5889 0.4561 2 
Carbamidomethyl 
(+57) 
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(K)NNNNEVIAAcLLTAVPVmK(V) 95% 4.4442 0.6011 2 
Carbamidomethyl 
(+57), Oxidation 
(+16) 
(K)NNNNEVIAAcLLTAVPVMK(V) 95% 4.0564 0.6292 2 
Carbamidomethyl 
(+57) 
(R)SFmEDTSESK(A) 95% 1.9839 0.3084 2 Oxidation (+16) 
(R)SFMEDTSESK(A) 95% 2.5511 0.4464 2 
 
(R)SFMEDTSESKAFADRDDKFYYNRLK(Y) 95% 2.3005 0.2497 2 
 
(K)TADDIIK(N) 95% 1.848 0.3038 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.8289 0.4453 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.3308 0.5202 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 4.0778 0.5866 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 4.1995 0.6168 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.8784 0.6191 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.8846 0.6358 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.8743 0.6169 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 4.0255 0.6248 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.8444 0.6269 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 4.645 0.6203 2 
 
(R)YHSVLDLK(D) 95% 2.1603 0.4056 2 
 
(R)YHSVLDLK(D) 95% 2.2131 0.4164 2 
 
(R)YHSVLDLK(D) 95% 3.1015 0.3761 2 
 
(R)YHSVLDLKDK(T) 95% 3.3904 0.4295 2 
 
 
5 
 
(K)EFGAFTDSMPYSHFTQTVGHYELK(L) 95% 2.8076 0.3451 2 
 
(K)EFGAFTDSmPYSHFTQTVGHYELK(L) 95% 3.8533 0.4398 2 Oxidation (+16) 
(K)EFGAFTDSMPYSHFTQTVGHYELK(L) 95% 3.8167 0.5562 2 
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(K)EFGAFTDSmPYSHFTQTVGHYELK(L) 95% 3.7671 0.4996 2 Oxidation (+16) 
(K)EFGAFTDSmPYSHFTQTVGHYELK(L) 95% 3.0922 0.6498 2 Oxidation (+16) 
(K)EFGAFTDSMPYSHFTQTVGHYELK(L) 95% 3.6848 0.594 2 
 
(K)EFGAFTDSmPYSHFTQTVGHYELK(L) 95% 3.5795 0.6809 2 Oxidation (+16) 
(R)FLSEEELPIFR(S) 95% 2.0485 0.3769 2 
 
(R)FLSEEELPIFR(S) 95% 2.7497 0.4121 2 
 
(K)FTEDAEDAGVVK(F) 95% 1.9638 0.4533 2 
 
(K)GFDPVLQIR(Y) 95% 2.1422 0.3535 2 
 
(K)GFDPVLQIR(Y) 95% 2.1592 0.4089 2 
 
(K)GFDPVLQIR(Y) 95% 2.6116 0.4633 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 2.6922 0.1972 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 1.7411 0.2801 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.1907 0.2819 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 2.5757 0.4736 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.0204 0.4715 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.9776 0.5301 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.9382 0.5711 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.4929 0.4983 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.5438 0.5409 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.3158 0.6045 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.942 0.5477 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.3527 0.5304 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.4723 0.5824 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.8811 0.5919 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.3781 0.6364 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.6041 0.6651 2 
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(K)LAEGYETHLVGIK(N) 95% 3.9174 0.577 2 
 
(K)LAEGYETHLVGIK(N) 95% 3.8285 0.568 2 
 
(K)LAEGYETHLVGIK(N) 95% 2.6841 0.5416 2 
 
(K)LAEGYETHLVGIK(N) 95% 2.9621 0.5854 2 
 
(R)LQEEHGNELPISAGFFFINPFEVVYYAGGTSNAFR(H) 95% 3.7704 0.2389 2 
 
(K)NNNNEVIAAcLLTAVPVmK(V) 95% 2.0647 0.304 2 
Carbamidomethyl 
(+57), Oxidation 
(+16) 
(K)NNNNEVIAAcLLTAVPVMK(V) 95% 4.9015 0.5321 2 
Carbamidomethyl 
(+57) 
(K)NNNNEVIAAcLLTAVPVMK(V) 95% 5.5906 0.6454 2 
Carbamidomethyl 
(+57) 
(K)NNNNEVIAAcLLTAVPVmK(V) 95% 5.4649 0.6472 2 
Carbamidomethyl 
(+57), Oxidation 
(+16) 
(K)PVYAAYTALK(K) 95% 2.3179 0.5104 1 
 
(K)RPENKKAHNKR(D) 95% 2.3335 0.3519 2 
 
(R)SFMEDTSESK(A) 95% 2.1611 0.4715 2 
 
(R)SFMEDTSESK(A) 95% 3.2271 0.4827 2 
 
(R)SFMEDTSESKAFADRDDKFYYNRLK(Y) 95% 2.4895 0.2766 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 2.1824 0.4472 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 2.9151 0.5825 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.8551 0.6046 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.9115 0.6095 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.841 0.6573 2 
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(R)VLVPLAYINFDEYIK(E) 95% 4.7115 0.4921 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 5.3317 0.4697 2 
 
(R)YHSVLDLK(D) 95% 2.9153 0.3376 2 
 
(R)YHSVLDLK(D) 95% 2.5794 0.2597 2 
 
(R)YHSVLDLK(D) 95% 2.0959 0.3878 2 
 
(R)YHSVLDLK(D) 95% 2.3946 0.3359 2 
 
(R)YHSVLDLK(D) 95% 2.3117 0.4447 2 
 
(R)YHSVLDLK(D) 95% 2.6753 0.4349 2 
 
(R)YNFYGVSGK(F) 95% 2.1073 0.3088 2 
 
(R)YNFYGVSGK(F) 95% 2.2127 0.4321 2 
 
 
 
 
 
 
 
 
 
 
6 
 
 
 
 
 
 
 
 
 
(K)AFADRDDKFYYNR(L) 95% 2.8946 0.3241 2 
 
(K)DIEKRPENKKAHNKRDNLQQQLDANEQK(I) 95% 2.5067 0.2803 2 
 
(K)EFGAFTDSMPYSHFTQTVGHYELK(L) 95% 2.7334 0.3898 2 
 
(K)EFGAFTDSMPYSHFTQTVGHYELK(L) 95% 2.9545 0.418 2 
 
(K)EFGAFTDSmPYSHFTQTVGHYELK(L) 95% 3.7106 0.4329 2 Oxidation (+16) 
(K)EFGAFTDSMPYSHFTQTVGHYELK(L) 95% 3.8545 0.5762 2 
 
(R)FLSEEELPIFR(S) 95% 3.4808 0.3861 2 
 
(K)FTEDAEDAGVVK(F) 95% 2.2151 0.5087 2 
 
(K)FTEDAEDAGVVK(F) 95% 3.9413 0.5577 2 
 
(K)FTNLTAK(E) 95% 1.6276 0.3672 2 
 
(K)GFDPVLQIR(Y) 95% 2.4032 0.3978 2 
 
(K)GFDPVLQIR(Y) 95% 2.9894 0.4362 2 
 
(K)GFDPVLQIR(Y) 95% 2.5624 0.4576 2 
 
(K)GFDPVLQIR(Y) 95% 2.7795 0.4635 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 2.182 0.2914 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 2.7318 0.3854 2 
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(R)GPVIDYENQELVHFFFNELSK(Y) 95% 2.9076 0.402 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 2.8712 0.5428 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.7394 0.5278 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.2636 0.4923 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.4504 0.4695 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.6661 0.5785 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 3.9738 0.5813 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.2002 0.5993 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.4892 0.6225 2 
 
(R)GPVIDYENQELVHFFFNELSK(Y) 95% 4.4412 0.6604 2 
 
(K)LAEGYETHLVGIK(N) 95% 1.8676 0.5717 2 
 
(K)LAEGYETHLVGIK(N) 95% 3.1284 0.5389 2 
 
(K)LAEGYETHLVGIK(N) 95% 2.6081 0.5021 2 
 
(K)LAEGYETHLVGIK(N) 95% 4.0605 0.5483 2 
 
(K)LAEGYETHLVGIK(N) 95% 3.5461 0.5956 2 
 
(K)LAEGYETHLVGIK(N) 95% 2.3948 0.6071 2 
 
(K)NNNNEVIAAcLLTAVPVMK(V) 95% 4.3057 0.6365 2 
Carbamidomethyl 
(+57) 
(K)NNNNEVIAAcLLTAVPVMK(V) 95% 5.2522 0.6737 2 
Carbamidomethyl 
(+57) 
(R)SFMEDTSESK(A) 95% 2.7233 0.5283 2 
 
(K)TADDIIK(N) 95% 1.5545 0.1994 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 2.3536 0.3564 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.7383 0.5229 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.5922 0.5891 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 3.75 0.6443 2 
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(R)VLVPLAYINFDEYIK(E) 95% 4.2015 0.6522 2 
 
(R)VLVPLAYINFDEYIK(E) 95% 5.1525 0.4842 2 
 
(R)YHSVLDLK(D) 95% 2.7918 0.4518 2 
 
(R)YHSVLDLK(D) 95% 2.6475 0.3004 2 
 
(R)YHSVLDLK(D) 95% 2.5334 0.4405 2 
 
(R)YHSVLDLK(D) 95% 2.8394 0.3679 2 
 
(R)YHSVLDLKDK(T) 95% 3.3734 0.2244 2 
 
(R)YNFYGVSGK(F) 95% 1.7362 0.5057 2 
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